Chitra Hosing, M.D.

Peer-Reviewed Articles

1. Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
2. Kadia, TM, Jain, A, Rausch, C, Bataller Torralba, A, Ravandi-Kashani, F, Jabbour, EJ, Qiao, W, Borthakur, G, Short, NJ, Montalban Bravo, G, Quesada, AE, Burger, JA, Ferrajoli, A, Wierda, WG, Hosing, C, Kantarjian, HM. Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. Blood Neoplasia 3(1), 2026. e-Pub 2026. PMID: 41536780.
3. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
4. Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol 77(5):571-581, 2025. e-Pub 2025. PMID: 39624016.
5. Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
6. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
7. Smallbone P, Shigle TL, Paslovsky O, Hosing C, Alousi A, Bashir Q, Aljawai Y, Ramdial J, Popat U, Champlin R, Shpall EJ, Oran B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
8. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
9. Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
10. Purnak S, Hosing C, Dabaja B, Bassett RL, Huen A, Duvic M. On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome. Clin Lymphoma Myeloma Leuk 24(12):827-836, 2024. e-Pub 2024. PMID: 39107202.
11. Ramdial, JL, Lin, R, Thall, PF, Valdez, B, Hosing, C, Srour, S, Popat, U, Qazilbash, MH, Alousi, AM, Barnett, M, Gulbis, A, Shigle, TL, Shpall, EJ, Andersson, BS, Nieto, Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone marrow transplantation 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
12. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
13. Angelidakis, G, Chemaly, RF, Sahasrabhojane, P, Morado-Aramburo, O, Jiang, Y, Bhatti, MM, Shpall, EJ, Hosing, C, Jain, P, Mahadeo, KM, Khawaja, F, Elhajj, P, Wargo, J, Jenq, RR, Ajami, NJ, Kebriaei, P, Ariza Heredia, E. Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies. Vaccines 12(9), 2024. e-Pub 2024. PMID: 39340100.
14. Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol 11(9):e671-e681, 2024. e-Pub 2024. PMID: 39067464.
15. Saengboon S, Ciurea SO, Popat UR, Ramdial JL, Bashir Q, Alousi AM, Chen J, Rondon G, Olson AL, Im JS, Hosing C, Shpall EJ, Champlin RE, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
16. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
17. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
18. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
19. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
20. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING AUTOLOGOUS CELL TRANSPLANTATION. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2023. PMID: 37437764.
21. Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther 30(2):203.e1-203.e9, 2024. e-Pub 2023. PMID: 38042257.
22. Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
23. Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplant Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
24. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
25. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
26. Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
27. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2022. PMID: 35605883.
28. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2022. PMID: 36470579.
29. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
30. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2022. PMID: 36503180.
31. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
32. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2022. PMID: 36502492.
33. Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. Transplant Cell Ther 28(11):788.e1-788.e5, 2022. e-Pub 2022. PMID: 36031077.
34. Kalariya, N, Ferreri, C, Dillard, C, Hawkins, MC, Manasanch, EE, Lee, HC, Weber, DM, Thomas, SK, Steiner, RE, Hosing, C, Qazilbash, MH, Popat, UR, Orlowski, R, Hildebrandt, MA, Patel, K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel. Clinical Lymphoma, Myeloma and Leukemia 22:S446, 2022. e-Pub 2022. PMID: 36164224.
35. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
36. Saengboon, S, Ramdial, JL, Saini, N, Olson, AL, Im, J, Hosing, C, Popat, UR, Shpall, E, Champlin, RE, Srour, S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S259-S260, 2022. e-Pub 2022. PMID: 36163857.
37. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
38. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
39. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
40. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
41. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
42. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
43. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
44. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
45. Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SK. Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res 6(2):e29393, 2022. e-Pub 2022. PMID: 35129455.
46. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
47. Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
48. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
49. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
50. Arrabi L, Jan A, Hosing C, Milton DR, Yeh J. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation. Eur J Haematol 107(6):634-641, 2021. e-Pub 2021. PMID: 34431142.
51. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
52. Hare J, DeLeon PG, Pool K, Reioux D, Fontenot M, Champlin RE, Eaton EN, Marin D, Rezvani K, Shpall EJ, Wilson JM, Hosing C. Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy 23(11):1029-1035, 2021. e-Pub 2021. PMID: 34247985.
53. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
54. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
55. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
56. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
57. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
58. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
59. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
60. Karri PV, Torres CA, Dailey Garnes NJ, Ronen S, Khawaja F, Bhatti MM, Hosing C, Patel AB. Disseminated atypical mycobacterial infection in an allogeneic stem cell transplant recipient. Dermatol Online J 27(6), 2021. e-Pub 2021. PMID: 34387060.
61. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
62. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
63. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
64. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. e-Pub 2021. PMID: 33398094.
65. Oran B, Saliba RM, Mehta RS, Alousi AM. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 2021. e-Pub 2021. PMID: 33471943.
66. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
67. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
68. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant. e-Pub 2020. PMID: 33009515.
69. Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
70. Whited LK, Handy VW, Hosing C, Chow E. Incidence of Viral and Fungal Infectious Complications after utilization of alternative donor sources in hematopoietic cell transplantation (HCT). Pharmacotherapy 40(8):773-787, 2020. e-Pub 2020. PMID: 32497299.
71. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
72. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant. e-Pub 2020. PMID: 32636464.
73. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol:1-8. e-Pub 2020. PMID: 32604096.
74. Saini NY, Marin D, Ledesma C, Delgado R, Rondon G, Popat U, Bashir Q, Hosing C, Nieto Y, Alousi A, Qazilbash MH, Ciurea SO, Shpall EJ, Khouri IF, Kantarjian HM, Jabbour E, Ravandi F, Champlin R, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood. e-Pub 2020. PMID: 32492706.
75. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
76. Khazal S, Ragoonanan D, Hosing C, Williams L, Medeiros LJ, Mahadeo KM, Thompson PA. Epstein - Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-barr virus mucocutaneous ulcer. Br J Haematol 189(2):e33-e36, 2020. e-Pub 2020. PMID: 32150641.
77. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
78. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
79. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. e-Pub 2020. PMID: 32107328.
80. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
81. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta RS, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin R. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood. e-Pub 2019. PMID: 31826244.
82. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
83. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
84. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RJ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31786242.
85. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
86. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
87. Jan AS, Hosing C, Aung F, Yeh J. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus. Transfusion 59(11):3519-3524, 2019. e-Pub 2019. PMID: 31587288.
88. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
89. Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol 94(6):E176-E180, 2019. e-Pub 2019. PMID: 30900768.
90. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
91. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
92. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. e-Pub 2019. PMID: 30948491.
93. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
94. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
95. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 30763728.
96. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2019. PMID: 30360985.
97. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. e-Pub 2018. PMID: 30300461.
98. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30308325.
99. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. e-Pub 2018. PMID: 30258129.
100. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
101. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
102. Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 101(3):389-398, 2018. e-Pub 2018. PMID: 29920784.
103. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res 24(16):3845-3856, 2018. e-Pub 2018. PMID: 30018119.
104. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30016656.
105. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
106. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma:1-11. e-Pub 2018. PMID: 30032678.
107. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
108. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
109. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
110. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
111. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
112. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):515-518, 2018. e-Pub 2018. PMID: 28673185.
113. Agha NH, Baker FL, Kunz HE, Graff R, Azadan R, Dolan C, Laughlin MS, Hosing C, Markofski MM, Bond RA, Bollard CM, Simpson RJ. Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β2-adrenergic receptor. Brain Behav Immun 68:66-75, 2018. e-Pub 2018. PMID: 29017969.
114. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, Investigators SS. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 378(1):35-47, 2018. e-Pub 2018. PMID: 29298160.
115. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk 18(1):e41-e50, 2018. e-Pub 2018. PMID: 29277360.
116. Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
117. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
118. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
119. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. e-Pub 2017. PMID: 28895206.
120. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
121. Ariza-Heredia EJ, Granwehr BP, Viola GM, Bhatti M, Kelley JM, Kochenderfer J, Hosing C. False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. Diagn Microbiol Infect Dis 88(4):305-307, 2017. e-Pub 2017. PMID: 28610774.
122. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
123. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554-1559, 2017. e-Pub 2017. PMID: 28379307.
124. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
125. Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31(7):1654-1657, 2017. e-Pub 2017. PMID: 28400618.
126. El Chaer F, Shah DP, Kmeid J, Ariza-Heredia EJ, Hosing CM, Mulanovich VE, Chemaly RF. Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. Cancer 123(12):2329-2337, 2017. e-Pub 2017. PMID: 28178369.
127. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
128. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
129. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
130. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
131. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(4):581-587, 2017. e-Pub 2017. PMID: 28063964.
132. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
133. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
134. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2017. PMID: 27741352.
135. Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):1-6, 2017. e-Pub 2017. PMID: 27348707.
136. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
137. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther 25(1):285-295, 2017. e-Pub 2017. PMID: 28129122.
138. Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant 52(1):20-27, 2017. e-Pub 2017. PMID: 27618682.
139. Thompson PA, Stingo F, Keating MJ, Wierda WG, O’Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for CLL: mixed T-cell chimaerism is associated with high relapse risk and inferior survival. BJH, 2017. e-Pub 2017.
140. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
141. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
142. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
143. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
144. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
145. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
146. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. e-Pub 2016. PMID: 27564097.
147. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res 47:100-8, 2016. e-Pub 2016. PMID: 27294334.
148. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. e-Pub 2016. PMID: 27247137.
149. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. e-Pub 2016. PMID: 27203405.
150. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
151. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
152. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML, Blood, Trials Network MTC. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. e-Pub 2016. PMID: 27118571.
153. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. e-Pub 2016. PMID: 27064056.
154. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma:1-9. e-Pub 2016. PMID: 26980288.
155. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. e-Pub 2016. PMID: 26950376.
156. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2016. PMID: 26795083.
157. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol. e-Pub 2016. PMID: 26773409.
158. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma:1-9. e-Pub 2015. PMID: 26472485.
159. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26702475.
160. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26(12):2490-5, 2015. e-Pub 2015. PMID: 26416896.
161. Kmeid J, Vanichanan J, Shah DP, El Chaer F, Azzi J, Ariza Heredia E, Hosing C, Mulanovich V, Chemaly RF. Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26638804.
162. Brammer JE, Khouri I, Gaballa S, Anderlini P, Tomuleasa C, Ahmed S, Ledesma C, Hosing C, Champlin RE, Ciurea SO. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26497906.
163. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant. e-Pub 2015. PMID: 26479980.
164. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26343946.
165. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica. e-Pub 2015. PMID: 26250579.
166. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26071868.
167. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. e-Pub 2015. PMID: 26039209.
168. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83-93, 2015. e-Pub 2015. PMID: 25458083.
169. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
170. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
171. Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25937397.
172. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25842049.
173. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 25963284.
174. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. e-Pub 2015. PMID: 25778529.
175. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. e-Pub 2015. PMID: 25721897.
176. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly R, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25708219.
177. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J 5:e357, 2015. e-Pub 2015. PMID: 26473529.
178. Saunders IM, Lahoti A, Chemaly RF, Trevino C, Westmoreland M, Hosing C. Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections. J Oncol Pharm Pract. e-Pub 2014. PMID: 25488905.
179. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-Atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
180. Aung FM, Lichtiger B, Bassett RL, Hosing C, Freireich EJ. Granulocyte Concentrates from a Single High-yield Apheresis Can Be Split to Support Multiple Patients. Leuk Lymphoma 55(11):2577-83, 2014. e-Pub 2014. PMID: 24456072.
181. Hamdi A, Afrough A, Muzzafar T, Popat UR, Hosing CM, Qazilbash MH, Lu G. Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clin Lymphoma Myeloma Leuk 14(5):e151-5, 2014. e-Pub 2014. PMID: 25022600.
182. Nesher L, Chemaly RF, Shah DP, Mulanovich VE, Hosing C, Rolston KV. Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. Am J Infect Control 42(10):1084-8, 2014. e-Pub 2014. PMID: 25278398.
183. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. e-Pub 2014. PMID: 25312977.
184. Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
185. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16(8):1153-7, 2014. e-Pub 2014. PMID: 24582458.
186. Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
187. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma:1-3. e-Pub 2014. PMID: 24882259.
188. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 14(3):e105-9, 2014. e-Pub 2014. PMID: 24502832.
189. Shah DP, Ghantoji SS, Ariza-Heredia EJ, Shah JN, El Taoum KK, Shah PK, Nesher L, Hosing C, Rondon G, Champlin RE, Chemaly RF. An Immunodeficiency Scoring Index to predict poor outcomes in hematopoietic cell transplant recipients with respiratory syncytial virus infections. Blood 123(21):3263-8, 2014. e-Pub 2014. PMID: 24700783.
190. Hosing C, Saliba RM, Hamerschlak N, Kutner JM, Sakashita AM, Kondo AT, Rodrigues M, Fernande JF, Chiattone A, Chiattone VC, Barros JC, Chiattone CS, Chiattone R, Popat U, Qazilbash M, Tang XW, Wu D, Majilis A, de Lima M, Anguita T. Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion 54(4):1081-7, 2014. e-Pub 2014. PMID: 24118027.
191. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant 20(3):295-308, 2014. e-Pub 2014. PMID: 24141007.
192. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
193. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol 31(33):4199-206, 2013. e-Pub 2013. PMID: 24127452.
194. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122(17):2965-73, 2013. e-Pub 2013. PMID: 24030379.
195. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
196. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 2013. e-Pub 2013. PMID: 23503529.
197. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
198. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 2013. e-Pub 2013. PMID: 23545991.
199. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
200. Shiue LH, Alousi AM, Wei C, Hosing CM, Duvic M, Ni X. Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. J Invest Dermatol 133(8):2098-100, 2013. e-Pub 2013. PMID: 23519332.
201. Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68(8):1872-80, 2013. e-Pub 2013. PMID: 23572228.
202. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
203. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
204. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 2013. e-Pub 2013. PMID: 23085830.
205. Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweeney P, Sullivan KM. Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. J Rheumatol 40(4):455-460, 2013. e-Pub 2013. PMID: 23418384.
206. Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E. CARs in Chronic Lymphocytic Leukemia - Ready to Drive. Curr Hematol Malig Rep 8(1):60-70, 2013. e-Pub 2013. PMID: 23225251.
207. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
208. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
209. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
210. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
211. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 2012. e-Pub 2012. PMID: 22750645.
212. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
213. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
214. Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin RE. An Adaptive Randomized Trial of Intermittent Dosing Schedule of Aerosolized Ribavirin in Cancer Patients with Respiratory Syncytial Virus Infections. J Infect Dis 206(9):1367-71, 2012. e-Pub 2012. PMID: 22927454.
215. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-9, 2012. e-Pub 2012. PMID: 22242817.
216. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent Hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the MD Anderson Cancer Center. Leuk Lymphoma 53(6):1239-41, 2012. e-Pub 2012. PMID: 22132837.
217. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
218. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
219. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
220. Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A, Vigil K, Adachi JA, Khoury AM, Tarrand J, Hosing C, Champlin R. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 119(12):2738-45, 2012. e-Pub 2012. PMID: 22246027.
221. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
222. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
223. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
224. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
225. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Post transplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
226. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
227. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
228. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 51(6):1300-13, 2011. e-Pub 2011. PMID: 21575005.
229. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
230. Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, Shulman H, Goldmuntz E, Mayes M, Parikh CR, Crofford L, Keyes-Elstein L, Furst D, Steen V, Sullivan KM. Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States. Biol Blood Marrow Transplant 17(5):674-81, 2011. e-Pub 2011. PMID: 20708086.
231. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II Trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 2011. e-Pub 2011. PMID: 20581887.
232. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
233. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol 29(3):294-302, 2011. e-Pub 2011. PMID: 21149654.
234. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
235. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That is Reversed with IL-2 Exvivo Expansion. J Immunother 33(7):684-696, 2010. e-Pub 2010. PMID: 20664358.
236. Kassis C, Champlin RE, Hachem RY, Hosing C, Tarrand JJ, Perego CA, Neumann JL, Raad II, Chemaly RF. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 16(9):1265-71, 2010. e-Pub 2010. PMID: 20304082.
237. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic Progenitor Cell Collection in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission after Imatinib Mysylate Therapy. Leuk Lymphoma 51(8):1478-1484, 2010. e-Pub 2010. PMID: 20658954.
238. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 16(8):1122-9, 2010. e-Pub 2010. PMID: 20178853.
239. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved Hepatitis B Virus Infection is not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 16(5):686-693, 2010. e-Pub 2010. PMID: 20056165.
240. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sezary Syndrome. J Clin Oncol 28(14):2365-2372, 2010. e-Pub 2010. PMID: 20351328.
241. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
242. Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 2010. PMID: 22282683.
243. Hosing C, Munsell M, Reuben J. A randomized study comparing chemotherapy followed by G-CS F alone or in combination with GM-CS F for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas. Journal of Blood Medicine 1:49-55, 2010. e-Pub 2010. PMID: 22282683.
244. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 15(12):1555-1562, 2009. e-Pub 2009. PMID: 19896079.
245. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologus hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-634, 2009. e-Pub 2009. PMID: 19998065.
246. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-2887, 2009. e-Pub 2009. PMID: 19654407.
247. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection. Biol Blood Marrow Transplant 15(10):1265-1270, 2009. e-Pub 2009. PMID: 19747634.
248. de Souza J, Saliba R, Patah P, Rondon G, Ribeiro R, Padua Silva L, Qazilbash M, Hosing C, Popat U, Efebera Y, Champlin R, de Lima M. Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 15(9):1094-1099, 2009. e-Pub 2009. PMID: 19660722.
249. Parikh G, Amjad A, Saliba R, Kazmi S, Khan Z, Lahoti A, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Popat U, Alousi A, Champlin R, Giralt S, Qazlibash M. Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation 15(7):812-816, 2009. e-Pub 2009. PMID: 19539212.
250. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(5):718-723, 2009. e-Pub 2009. PMID: 19450756.
251. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 2009. e-Pub 2009. PMID: 19237479.
252. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor Hematopoietic Stem Cell Mobilizers: A Single Institution Study of Incidence and Risk Factors in Patients with Recurrent or Relapsed Lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
253. DiPersio J, Stadtmauer E, Nademanee A, Micallef I, Stiff P, Kaufman J, Maziarz R, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra, Investigators FT. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113(23):5720-5726, 2009. e-Pub 2009. PMID: 19363221.
254. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature Results of the M. D. Anderson Cancer Center Risk-Adapted Transplantation Strategy in Mantle Cell Lymphoma. Blood 113(18):4144-4152, 2009. e-Pub 2009. PMID: 19168784.
255. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
256. Qazilbash M, Saliba R, Nieto, Parikh G, Pelosini M, Khan F, Jones R, Hosing C, Mendoza F, Weber D, Wang M, Popat U, Alousi A, Anderlini P, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biology of Blood and Marrow Transplantation 14(12):1401-1407, 2008. e-Pub 2008. PMID: 19041063.
257. Alousi A, Saliba R, Okoroji G, Macapinlac H, Hosing C, Korbling M. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-792, 2008. e-Pub 2008. PMID: 18564354.
258. Khouri I, McLaughlin P, Saliba R, Hosing C, Korbling M, Lee M, Medeiros J, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu S, Ueno NT, Samuels B, Hagemeister F, Kwak L, Champlin R. Eight-year Experience with Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma after Nonmyeloablative Conditioning with Fludarabine, Cyclophosphamide, and Rituximab. Blood 111(12):5530-5536, 2008. e-Pub 2008. PMID: 18411419.
259. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 41(9):771-8, 2008. e-Pub 2008. PMID: 18209724.
260. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2008. e-Pub 2008. PMID: 18223284.
261. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2008. e-Pub 2008. PMID: 17989720.
262. Hosing C, Saliba R, Okoroji G, Popat U, Couriel D, Ali T, de Padua Silva L, Kebriaei P, Alousi A, de Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin R, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Annals of Oncology 19(6):1166-1171, 2008. e-Pub 2008. PMID: 18272911.
263. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 2007. e-Pub 2007. PMID: 17611563.
264. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110(9):3456-62, 2007. e-Pub 2007. PMID: 17652620.
265. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
266. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
267. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 2007. e-Pub 2007. PMID: 17497648.
268. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 2007. e-Pub 2007. PMID: 17382253.
269. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyper-acute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751-2758, 2007. e-Pub 2007. PMID: 17138825.
270. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
271. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
272. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 38(6):421-6, 2006. e-Pub 2006. PMID: 16892072.
273. Hosing C, Saliba RM, Körbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(7):1290-4, 2006. e-Pub 2006. PMID: 16923559.
274. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilization in patients with multiple myeloma. Br J Haematol 133(5):533-7, 2006. e-Pub 2006. PMID: 16681642.
275. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 12(1) Suppl.2(8):37-40, 2006. e-Pub 2006. PMID: 16368882.
276. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106(5):1084-9, 2006. e-Pub 2006. PMID: 16456814.
277. Couriel D, Hosing C, Saliba R, Shpall EJ, Anderlini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 107(8)(1 Suppl 2):3074-3080, 2006. e-Pub 2006. PMID: 16399600.
278. Qazilbash M, Ueno NT, Hosing C, de Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi J, Champlin R. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation 38(5):393-4, 2006. e-Pub 2006. PMID: 16845427.
279. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80(1):43-5, 2005. e-Pub 2005. PMID: 16138357.
280. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130(3):409-17, 2005. e-Pub 2005. PMID: 16042691.
281. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157-62, 2005. e-Pub 2005. PMID: 15937511.
282. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 2005. e-Pub 2005. PMID: 15806128.
283. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 2005. e-Pub 2005. PMID: 15800314.
284. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2005. e-Pub 2005. PMID: 15682071.
285. Khouri I, Saliba R, Hosing C, Okoroji G, Acholonu S, Anderlini P, Couriel D, de Lima M, Donato M, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning J, Pro B, Shpall E, Younes A, McLaughlin P, Champlin R. Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas. Journal of Clinical Oncology 23:2240-2247, 2005. e-Pub 2005. PMID: 15800314.
286. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 31(12):2513-6, 2004. e-Pub 2004. PMID: 15570660.
287. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649-54, 2004. e-Pub 2004. PMID: 15069017.
288. Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-23, 2004. e-Pub 2004. PMID: 15197204.
289. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33(10):1015-23, 2004. e-Pub 2004. PMID: 15048145.
290. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178-85, 2004. e-Pub 2004. PMID: 14993883.
291. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32(1):28-35, 2004. e-Pub 2004. PMID: 14725898.
292. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 2003. e-Pub 2003. PMID: 12881308.
293. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102(8):3052-9, 2003. e-Pub 2003. PMID: 12842990.
294. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122(1):128-34, 2003. e-Pub 2003. PMID: 12823354.
295. Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri I. Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma 44(5):829-32, 2003. e-Pub 2003. PMID: 12802922.
296. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 2003. e-Pub 2003. PMID: 12702528.
297. Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 31(6):459-65, 2003. e-Pub 2003. PMID: 12665841.
298. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 13(3):450-9, 2002. e-Pub 2002. PMID: 11996478.
299. Hosing C, Champlin RE. The choice of allogeneic or autologous hematopoietic transplantation for NHL. Cytotherapy 4(3):259-69, 2002. e-Pub 2002. PMID: 12194722.
300. Hosing C, Freedman RS, McLaughlin P, Malpica A, Fornage BD, Kudelka AP. Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Am J Clin Oncol 24(2):204-8, 2001. e-Pub 2001. PMID: 11319299.

Invited Articles

1. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med 3(12):1435-43, 2014. e-Pub 2014. PMID: 25378655.
2. Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clin Lymphoma Myeloma Leuk 14S:S18-S22, 2014. e-Pub 2014. PMID: 25486950.
3. Hosing C, de Lima M, Shpall EJ. Mesenchymal Stromal Cells and Umbilical Cord Blood Transplantation. Adult and Embryonic Stem Cells:33-47, 2012. e-Pub 2012.
4. Hosing C. Hematopoietic Stem Cell Mobilization with G-CSF. Methods Mol Biol 904:37-47, 2012. e-Pub 2012. PMID: 22890920.
5. Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 22(7):1471-7, 2011. e-Pub 2011. PMID: 21551006.
6. Rodrigues CA, Patah PA, Novis YA, Hosing C, de Lima M. The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings. Curr Hematol Malig Rep 6(1):47-57, 2011. e-Pub 2011. PMID: 21190142.
7. Gribben JG, Hosing C, Maloney DG. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant 17(1 Suppl):S63-70, 2011. e-Pub 2011. PMID: 21195313.
8. Hosing C. Hematopoietic Stem Cell Transplantation for the management of follicular lymphoma. Stem Cells and Cloning: Advances and Applications 3:69-80, 2010. e-Pub 2010.
9. Hosing C, Khouri I. Nonmyeloablative allogeneic stem cell transplantation for lymphoid malignancies using fludarabine based regimens. Non-myeloablative stem cell transplantation (NST) Giralt and Slavin (eds):73-82, 2000. e-Pub 2000.

Review Articles

1. Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B, Hosing C, Tewari P, Khazal S. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci 24(12), 2023. e-Pub 2023. PMID: 37373245.
2. Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JR. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
3. Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 58:14-22, 2017. e-Pub 2017. PMID: 28380402.
4. Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJ. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne) 2:89, 2015. e-Pub 2015. PMID: 26697430.
5. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. e-Pub 2009. PMID: 19778850.
6. Lee HJ, Gulbis A, De Padua Silva L, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SO. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42(1):67-9, 2008. e-Pub 2008. PMID: 18347568.
7. Hong DS, Jacobson KL, Raad II, de Lima M, Anderlini P, Fuller GN, Ippoliti C, Cool RM, Leeds NE, Narvios A, Han XY, Padula A, Champlin RE, Hosing C. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis 37(8):1044-9, 2003. e-Pub 2003. PMID: 14523768.
8. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 17(1):94-100; discussion 103-7, 2003. e-Pub 2003. PMID: 12599934.
9. Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 30(8):543-6, 2002. e-Pub 2002. PMID: 12379897.

Other Articles

1. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
2. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204]. Transplant Cell Ther, 2024. PMID: 39561968.

Abstracts

1. Popat U, Jr RB, Thall P, Alousi A, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Valdez B, Qazilbash M, Champlin R, Shpall E, Andersson B. Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study. ASCO 2025, 2025. e-Pub 2025.
2. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASTCT 2025, 2025. e-Pub 2025.
3. Aljawai YM, Smallbone P, Alousi AM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Kebriaei P, Marin D, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rezvani K, Champlin RE, Shpall Mehta EJRS. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. ASTCT 2025, 2025. e-Pub 2025.
4. Kim K, Huen AO, Dai J, Lohray R, Dabaja B, Gunther JR, Wu SY, Torres-Cabala CA, Nair R, Malpica L, Nieto Y, Ramdial JL, Hosing CM, Srour SA, Iyer SP. Outcomes of Allogeneic Stem-Cell Transplant in Large-Cell Transformation of Mycosis Fungoides. ASTCT 2025, 2025. e-Pub 2025.
5. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. ASTCT 2025, 2025. e-Pub 2025.
6. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. ASTCT 2025, 2025. e-Pub 2025.
7. Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. ASTCT 2025, 2025. e-Pub 2025.
8. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. ASH 2024, 2024. e-Pub 2024.
9. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. ASH 2024, 2024. e-Pub 2024.
10. Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. ASH 2024, 2024. e-Pub 2024.
11. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Valero YA, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau SM, Kadia TM, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer MA, Huang X, Garcia-Manero G. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. ASH 2024, 2024. e-Pub 2024.
12. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. ASH 2024, 2024. e-Pub 2024.
13. Lohray R, Feng L, Huen AO, Ogundipe I, Malpica L, Dabaja BS, Dai J, Gunther JR, Hosing C, Miranda RN, Medeiros L, Srour SA, Ramdial J, Vega F, Noorani M, Ayers AA, Fang PQ, Fayad LE, Pinnix CC, Duvic M, Xu J, Flowers CR, Wu SY, Kim K, Torres-Cabala CP, Iyer SP, Nair R. Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases. ASH 2024, 2024. e-Pub 2024.
14. Ramdial J, Clemente L, Banerjee P, Dabaja BS, Al-Atrash G, Alousi AM, Oran B, Popat U, Im JS, Srour SA, Chen G, Kebriaei P, Hosing C, Marin D, Rezvani K, Shpall EJ, Champlin RE. Phase II Clinical Trial of “Off-the-Shelf" NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies. ASH 2024, 2024. e-Pub 2024.
15. Alatrash G, Knape C, Whited L, Sui D, Haymaker CL, Yeh J, Marcotulli M, Sukhumalchandra P, John LS, Lu H, Duenas DE, Wistuba I, Perez JM, Espiridion BS, Bassett RL, Kadia TM, DiNardo CD, Ravandi F, Ramdial J, Mehta RS, Alousi AM, Oran B, Khouri IF, Bashir Q, Hosing C, Qazilbash MH, Im JS, Kebriaei P, Bachireddy P, Molldrem JJ, Jorgensen JL, Wang SA, Wang W, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Daver N. A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. ASH 2024, 2024. e-Pub 2024.
16. Smallbone P, Saengboon S, Bashir Q, Nelson BE, Ramdial J, Saini NY, Hosing C, Popat UR, Delgado R, Becnel M, Lee HC, Orlowski R, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Impact of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) on AL Amyloidosis Outcomes. ASTCT 2024, 2024. e-Pub 2024.
17. Ramdial J, Valdez BC, Lin R, Thall P, Wei A, Hosing C, Srour SA, Popat UR, Qazilbash MH, Alousi AM, Barnett M, Gulbis AM, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Gemcitabine (Gem) /Clofarabine (Clo) /Busulfan (Bu) (GemCloBu): A New Myeloablative Conditioning Regimen with Reduced Toxicity and High Activity for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. ASTCT 2024, 2024. e-Pub 2024.
18. Patel RD, Feng L, Gurumurthi A, Westin JR, Nastoupil LJ, Nair R, Iyer SP, Fayad L, Samaniego F, Steiner R, Nieto Y, Oran B, Hawkins M, Chihara D, Adkins S, Shpall EJ, Ramdial J, Strati P, Hosing C, Neelapu SS, Ahmed S. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients. ASTCT 2024, 2024. e-Pub 2024.
19. Ramdial J, Lin R, Thall P, Valdez BC, Hosing C, Srour SA, Popat UR, Qazilbash MH, Alousi AM, Shpall EJ, Barnett M, Jimenez E, Gulbis AM, Shigle TL, Andersson BS, Nieto Y. A Comparison of Gemcitabine/Clofarabine/Busulfan (Gem/Clo/Bu) Myeloablative Conditioning with Fludarabine/Melphalan (Flu/Mel) Reduced Intensity Conditioning for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. ASTCT 2024, 2024. e-Pub 2024.
20. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood 142(Supplement 1), 2023. e-Pub 2023.
21. Subramanian N, Gurumurthi A, Pasvolsky O, Ferreri C, Lee HC, Manasanch EE, Thomas SK, Weber DM, Gaballa M, Dillard C, Becnel M, Hosing C, Lin P, Amini B, Qazilbash MH, Kalariya N, Hawkins M, Ahmed S, Orlowski RZ, Patel KK. Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM). Blood 142(Supplement 1), 2023. e-Pub 2023.
22. Sarkar S, Connors JS, Sheikh I, Rav E, Wang Z, Bassett RL, Straubel M, Mahadeo KM, Tewari P, Petropoulos D, Hosing C, Ragoonanan D, Khazal S, Fucanan A, Bibal C. The Impact of Leukapheresis Collection on Patients Undergoing Chimeric Antigen T-Cell Receptor Therapy with Tisagenlecleucel. Blood 142(Supplement 1), 2023. e-Pub 2023.
23. Nieto Y, Banerjee P, Kaur I, Griffin L, Barnett M, Ganesh C, Borneo Z, Bassett RL, Kerbauy LN, Basar R, Kaplan M, Esqueda D, Ramdial J, Ahmed S, Hosing C, Srour SA, Alousi A, Qazilbash MH, Steiner RE, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results. Blood 142(Supplement 1), 2023. e-Pub 2023.
24. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 142(Supplement 1), 2023. e-Pub 2023.
25. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 142(Supplement 1), 2023. e-Pub 2023.
26. Bashir Q, Konopleva MY, Abueg G, Ramdial J, Hosing C, Srour SA, Alousi A, Popat UR, Nieto Y, Alatrash G, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 142(Supplement 1), 2023. e-Pub 2023.
27. Pasvolsky O, Hildebrandt M, Subramanian N, Ferreri C, Lee HC, Manasanch EE, Thomas SK, Weber DM, Gaballa M, Dillard C, Becnel M, Hosing C, Lin P, Amini B, Qazilbash MH, Kalariya N, Orlowski RZ, Patel KK. Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience. Blood 142(Supplement 1), 2023. e-Pub 2023.
28. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee HC, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood 142(Supplement 1), 2023. e-Pub 2023.
29. Hosing C, Braunstein Z, McLaughlin E, Valdez BC, Andersson BS, Popat UR, Vasu S, Bezzera E, Sanchez-Petitto G, Wall SA, Jaglowski SM, Penza S, Choe H, Wei L, Nakkula R, Cash A, Champlin RE, Lima MD, Devine SM, Lee DA, Brammer JE. Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial. Blood 142(Supplement 1), 2023. e-Pub 2023.
30. Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour SA, Tanner MR, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Weber DM, Becnel MR, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. Blood 142(Supplement 1), 2023. e-Pub 2023.
31. Popat UR, Lontos K, Bassett RL, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Oran B, Olson AL, Qazilbash MH, Ramdial JL, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules. ASCO 2023, 2023. e-Pub 2023.
32. Uday R Popat MD, Saliba PhD RM, Rohtesh S Mehta MD, MPH, MS, Amin M Alousi MD, Al-Atrash G, Qaiser Bashir MD, Julianne Chen BS, Gulbis PharmD AM, Chitra M Hosing MD, Jin S Im MD, PhD, Partow Kebriaei MD, Issa F Khouri MD, Kawedia PharmD JD, PhD, David Marin MD, Yago Nieto MD, PhD, Amanda Olson MD, Betul Oran MD, Jeremy Ramdial MD, Neeraj Y Saini MD, MB ChB SAS, MS, Katayoun Rezvani MD, PhD, Muzaffar H Qazilbash MD, Hagop Kantarjian MD, Borje S Andersson MD, PhD, Champlin RE, Elizabeth J Shpall MD. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplantation and Cellular Therapy 29(2):S164-S165, 2023. e-Pub 2023.
33. Oren Pasvolsky MD, Bassett R, Ghanem S, Branko Cuglievan MD, Priti T, Hosing C, Srour S, Jeremy L Ramdial MD, Kris Michael Mahadeo MD, Khazal SJ, Petropoulos D, Popat UR, Muzaffar H Qazilbash MD, Partow Kebriaei MD, Champlin RE, Shpall EJ, Yago Nieto MD, PhD. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy 29(2):S378-S379, 2023. e-Pub 2023.
34. Kok Hoe Chan MD, Jeremy L Ramdial MD, Chitra Hosing MD, MB ChB SAS, MS, Amin M Alousi MD, Partow Kebriaei MD, Popat UR, Muzaffar H Qazilbash MD, Sairah Ahmed MD, Swaminathan P Iyer MD, Hun Ju Lee MD, Ranjit Nair MD, Raphael Steiner MD, Paolo Strati MD, Bouthaina Dabaja MD, Penny Fang MD, Jillian R Gunther MD, PhD, Chelsea Pinnix MD, PhD, Susan Y Wu MD, Branko Cuglievan MD, Kris Michael Mahadeo MD, Champlin RE, Shpall EJ, Yago Nieto MD, PhD. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT). Transplantation and Cellular Therapy 29(2):S382, 2023. e-Pub 2023.
35. Saengboon S, Issa F Khouri MD, Chitra Hosing MD, Jeremy L Ramdial MD, Neeraj Y Saini MD, Akin S, Shi D, Raphael Steiner MD, Malpica L, Sairah Ahmed MD, Jason R Westin MD, MS, FACP, Bouthaina Dabaja MD, Susan Y Wu MD, Amin M Alousi MD, Partow Kebriaei MD, Muzaffar H Qazilbash MD, Popat UR, Champlin RE, Shpall EJ, Yago Nieto MD, PhD, MB ChB SAS, MS. Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL). Transplantation and Cellular Therapy 29(2):S386, 2023. e-Pub 2023.
36. Shi D, Chitra Hosing MD, Issa F Khouri MD, Saengboon S, Neeraj Y Saini MD, Jeremy L Ramdial MD, Akin S, Qaiser Bashir MD, Raphael Steiner MD, Bouthaina Dabaja MD, Chelsea Pinnix MD, PhD, Sairah Ahmed MD, Amin M Alousi MD, Paolo Anderlini MD, Partow Kebriaei MD, Muzaffar H Qazilbash MD, Popat UR, Shpall EJ, Champlin RE, Yago Nieto MD, PhD, MB ChB SAS, MS. Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL). Transplantation and Cellular Therapy 29(2):S383, 2023. e-Pub 2023.
37. Agbedia OO, MD, MPH, Prakash R, BS, Xu J, MD, Becnel MR, MD, Nair R, MD, Steiner RE, MD, Feng L, MS, Lee HJ, MD, Strati P, MD, Ahmed S, MD, Parmar S, MD, MSCI, Nieto Y, MD, Hosing C, MD, Westin J, MD, Nastoupil LJ, MD, Vo A, Samaniego F, MD, Fowler NH, MD, Saini N, MD, Khouri IF, MD, Im JS, MD, PhD, Fayad L, MD, Jain P, MBBS, MD, DM, PhD, Wang ML, MD, Miranda RN, MD, Vega F, MD, PhD, Medeiros J, MD, PhD, Oki Y, Flowers CR, MD, Neelapu SS, MD, Iyer SP, MD. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. ASH 2022, 2022. e-Pub 2022.
38. Hosing C, MD, McLaughlin E, MS, Braunstein Z, MD, Valdez BC, PhD, Wei L, PhD, Popat UR, MD, Andersson BS, MD, PhD, Vasu S, MBBS, Larkin KT, MD, Jaglowski S, MD, MPH, Penza S, MD, Saad A, MD, Choe H, MD, Wall SA, MD, MPH, Cash A, Nakkula R, Champlin RE, MD, de Lima MJ, MD, Lee DA, MD, PhD, Brammer JE, MD. Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial. ASH 2022, 2022. e-Pub 2022.
39. Nieto Y, MD, Valdez BC, PhD, Thall PF, PhD, Ramdial JL, MD, Srour SA, MD, MS, Hosing C, MD, Saini N, MD, Alousi AM, MD, Qazilbash MH, MD, Popat UR, MD, Gulbis A, PharmD, Shigle TL, PharmD, Bassett R, MS, Guillermo-Pacheco M, Ledesma C, Strati P, MD, Ahmed S, MD, Steiner R, MD, Westin J, MD, Nair R, MD, Iyer SP, MD, Champlin RE, MD, Shpall EJ, MD, Andersson BS, MD, PhD. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. ASH 2022, 2022. e-Pub 2022.
40. Nieto Y, MD, Banerjee PP, PhD, Kaur I, PhD, Griffin L, Ganesh C, Kerbauy L, MD, Basar R, MD, Kaplan M, MS, Islam S, Esqueda D, Bassett R, MS, Timmons M, PA-C, Ramdial JL, MD, Srour SA, MD, MS, Saini N, MD, Hosing C, MD, Ahmed S, MD, Iyer SP, MD, Alexis K, MD, Emig M, MD, Harstrick A, MD, Shpall EJ, MD, Rezvani K, MD. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. ASH 2022, 2022. e-Pub 2022.
41. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. ASH 2022, 2022. e-Pub 2022.
42. Khouri IF, MD, Hwang H, Neelapu SS, MD, Wang X, MS, Hosing C, MD, Ahmed S, MD, Kebriaei P, MD, Daher M, MD, Olson AL, MD, Anderlini P, MD, Im JS, MD, PhD, Westin J, MD, Shpall EJ, MD, Champlin RE, MD, Nastoupil LJ, MD. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. ASH 2022, 2022. e-Pub 2022.
43. Mirza A, MD, MPH, Hosing C, MD, Foss FM, MD, Kim S, PhD, Moskop A, MD, MS, Oloyede T, Ahmed S, MD, Hematti P, MD, Turtle CJ, MBBS, PhD, Pasquini MC, MD, MS, Gowda L, MD. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). ASH2022, 2022. e-Pub 2022.
44. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. ASH 2022, 2022. e-Pub 2022.
45. Sheng A, MD, Gordon MJ, MD, Ahmed S, MD, Steiner RE, MD, Strati P, MD, Westin J, MD, Hosing C, MD, Kebriaei P, MD, Shpall EJ, MD, Neelapu SS, MD, Nastoupil LJ, MD. Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies. ASH 2022, 2022. e-Pub 2022.
46. Champlin RE, MD, Lustig EB, PhD, Bashir Q, MD, Oran B, MD, MSc, Kornblau SM, MD, Hosing C, MD, Alousi AM, MD, Popat UR, MD, McCarty JM, Thall PF, PhD, Dabaja BS, MD, Liu W, MD, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, MD, Fang P, MD, Kaur I, PhD, Rezvani K, MD, Shpall EJ, MD, Reisner Y, PhD. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). ASH 2022, 2022. e-Pub 2022.
47. Pasvolsky O, MD, Saliba RM, PhD, Ledesma C, Popat UR, MD, Alousi AM, MD, Olson AL, MD, Oran B, MD, MSc, Hosing C, MD, Bashir Q, MD, Qazilbash MH, MD, Short N, MD, Ravandi F, MD, Champlin RE, MD, Shpall EJ, MD, Kebriaei P, MD. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. ASH 2022, 2022. e-Pub 2022.
48. Nieto Y, Banerjee P, Kaur I, Bassett R, Kerbauy L, Basar R, Kaplan M, Griffin L, Esqueda D, Ganesh C, Barnett M, Alousi A, Hosing C, Ramdial J, Saini N, Srour S, Alexis K, Harstrick A, Shpall EJ, Rezvani K. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. AACR 2022, 2022. e-Pub 2022.
49. Nelson BE, MBBS, Ramdial J, MD, Bashir Q, MD, Saini NY, MD, Hosing C, MD, Popat UR, MD, Delgado R, Lee HC, MD, Kaufman G, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD, Srour SA, MD. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplantation and Cellular Therapy 28(3):S414-S415, 2022. e-Pub 2022.
50. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Kawedia JD, PharmD, PhD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Kadia TM, MD, Kantarjian H, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplantation and Cellular Therapy 28(3):S293, 2022. e-Pub 2022.
51. Popat UR, MD, Mehta RS, MD, MPH, MS, Thall P, PhD, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Daver N, MD, Ravandi F, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplantation and Cellular Therapy 28(3):S78-S79, 2022. e-Pub 2022.
52. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Gulbis AM, PharmD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Kadia TM, MD, Konopleva M, MD, PhD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy 28(3):S82-S83, 2022. e-Pub 2022.
53. Srour SA, MD, Saengboon S, Nelson BE, MBBS, Ramdial J, MD, Bashir Q, MD, Vickers MR, Saini NY, MD, Hosing C, MD, Popat UR, MD, Delgado R, Lee HC, MD, Kaufman G, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Transplantation and Cellular Therapy 28(3):S426, 2022. e-Pub 2022.
54. Saengboon S, Cox N, Olson A, MD, Khawaja F, MD, Daher M, MD, Im JS, MD, PhD, Chen J, BS, Hosing C, MD, Qazilbash MH, MD, Shpall EJ, MD, Champlin RE, MD, Srour SA, MD. Impact of Letermovir Prophylaxis on Clinically Significant CMV Infection and Overall Survival after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 28(3):S367, 2022. e-Pub 2022.
55. Qazilbash MH, MD, Bashir Q, MD, Rauf M, Sui D, MS, Srour SA, MD, Popat UR, MD, Saini NY, MD, Hosing C, MD, Ramdial J, MD, Manasanch E, MD, Lee HC, MD, Kaufman G, MD, Thomas S, MD, Weber D, MD, Becnel M, MD, Tang G, MD, PhD, Orlowski RZ, MD, PhD, Guzman M, Champlin CRN, MD, Shpall EJ, MD, Patel KK, MD, MSc. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 28(3):S404-S405, 2022. e-Pub 2022.
56. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Kawedia JD, PharmD, PhD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Rezvani K, MD, PhD, Qazilbash MH, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplantation and Cellular Therapy 28(3):S83-S84, 2022. e-Pub 2022.
57. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MD, Hosing C, MD, Im JS, MD, PHD, Kebriaei P, MD, Gulbis A, Marin D, MD, Nieto Y, MD, Olson AL, MD, Oran B, MD, MS, Ramdial JL, MD, Saini N, MD, Srour SA, Valdez BC, PhD, Rezvani K, MD, PHD, Qazilbash MH, MD, Kadia TM, MD, Konopleva M, MD, PhD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. ASH 2021, 2021. e-Pub 2021.
58. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MD, Hosing C, MD, Im JS, MD, PHD, Kebriaei P, MD, Kawedia JD, BPharm, Khouri IF, MD, Marin D, MD, Nieto Y, MD, Olson AL, MD, Oran B, MD, MS, Ramdial JL, MD, Saini N, MD, Srour SA, Rezvani K, MD, PHD, Qazilbash MH, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. ASH 2021, 2021. e-Pub 2021.
59. Herrera AF, MD, Zain J, MD, Savage KJ, MD, MSc, FRCPC, Feldman TA, MD, Brammer JE, MD, Chen L, PhD, Popplewell LL, MD, FACP, Budde LE, MD, PhD, Mei M, MD, Leslie LA, MD, Nair R, MD, Hosing C, MD, Peters L, Forman SJ, MD, Rosen ST, MD, Kwak LW, MD, PhD, Iyer SP, MD. Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. ASH 2021, 2021. e-Pub 2021.
60. Al-Juhaishi T, MD, Malek AE, MD, Milton DR, MS, Ramdial JL, MD, Daher M, MD, Olson AL, MD, Srour SA, Alatrash G, DO, PhD, Oran B, MD, MS, Mehta RS, MD, MPH, MS, Khouri IF, MD, Bashir Q, MD, Shah N, MD, Ciurea SO, MD, Rondon G, MD, Maadani F, BS, MT, Hosing C, MD, Marin D, MD, Kebriaei P, MD, Rezvani K, MD, PHD, Nieto Y, MD, Anderlini P, MD, Alousi AM, MD, Qazilbash MH, MD, Popat UR, MD, Champlin RE, MD, Shpall EJ, MD, Mulanovich V, MD, Ahmed S, MD. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2021, 2021. e-Pub 2021.
61. Dickinson M, MBBS, Hamad N, Bryant CE, MBBS, PhD, FRACP, FRCPA, Borthakur G, MD, Hosing C, MD, Shook D, MD, Tan J, PhD, Rajangam K, MD, PhD, Liu H, MD, PhD, Kennedy GA, MBBS, FRACP, FRCPA, McSweeney PA, MD, Hill BT, MD. A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies. ASH 2021, 2021. e-Pub 2021.
62. Popat UR, MD, Bassett R, MS, Thall PF, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MD, Hosing C, MD, Im JS, MD, PHD, Kebriaei P, MD, Marin D, MD, Nieto Y, MD, Olson AL, MD, Oran B, MD, MS, Ramdial JL, MD, Saini N, MD, Srour SA, Valdez BC, PhD, Rezvani K, MD, PHD, Qazilbash MH, MD, Daver N, MD, Ravandi F, MBBS, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD, Mehta RS, MD, MPH, MS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. ASH 2021, 2021. e-Pub 2021.
63. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MD, Hosing C, MD, Im JS, MD, PHD, Kebriaei P, MD, Kawedia JD, BPharm, Khouri IF, MD, Marin D, MD, Nieto Y, MD, Olson AL, MD, Oran B, MD, MS, Ramdial JL, MD, Saini N, MD, Srour SA, Valdez BC, PhD, Rezvani K, MD, PHD, Qazilbash MH, MD, Kadia TM, MD, Kantarjian H, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. ASH 2021, 2021. e-Pub 2021.
64. Malpica-Castillo L, MD, Feng L, MS, Xu J, MD, Nair R, MD, Elias A, Jain P, MBBS, MD, DM, PhD, Chihara D, MD, Steiner R, MD, Fayad L, MD, Samaniego F, MD, Ahmed S, MD, Fowler NH, MD, Nastoupil L, MD, Srour SA, Nieto Y, MD, Hosing C, MD, Miranda RN, MD, Vega F, MD, PhD, Pinnix CC, MD, PhD, Gunther JR, MD, PhD, Fang P, MD, Wu S, MD, Dabaja BS, MD, Medeiros J, MD, PhD, Wang M, MD, Neelapu SS, MD, Flowers CR, Iyer SP, MD. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. ASH 2021, 2021. e-Pub 2021.
65. Nelson BE, MBBS, Ramdial JL, MD, Bashir Q, MD, Saini N, MD, Hosing C, MD, Popat UR, MD, Delgado R, Lee HC, MD, Kaufman GP, MD, Orlowski RZ, Champlin RE, MD, Qazilbash MH, MD, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. ASH 2021, 2021. e-Pub 2021.
66. Hosing C, MD, Braunstein Z, MD, Ali AM, MD, Valdez BC, PhD, Andersson BS, MD, PhD, Popat UR, MD, Vasu S, MBBS, Larkin K, MD, Penza S, MD, Choe H, MD, Saad A, MD, de Lima MJ, MD, Wei L, PhD, McLaughlin E, MS, Nakkula R, Campbell A, BS, Trikha P, PhD, Puto M, PharmD, William BM, MD, Champlin RE, MD, Lee DA, MD, PhD, Brammer JE, MD. Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial. ASH 2021, 2021. e-Pub 2021.
67. Afrough A, MD, Srour SA, MD, MS, Bashir Q, MD, Saini N, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Delgado R, Murphy R, PA-C, Manasanch EE, MD, Lee HC, MD, Kaufman GP, MD, Patel KK, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. ASH 2020, 2020. e-Pub 2020.
68. Greenbaum U, MD, Strati P, MD, Saliba RM, PhD, Torres J, Rondon G, Nieto Y, MD, Hosing C, MD, Srour SA, MD, MS, Westin J, MD, Fayad L, Lee HJ, MD, Iyer SP, MD, Nastoupil LJ, MD, Parmar S, MD, MSCI, Rodriguez MA, MD, Samaniego F, MD, Steiner RE, MD, Wang M, MD, Pinnix CC, MD, PhD, Flowers C, MD, MS, Tummala S, MD, Ramdial J, MD, Yalniz FF, Hawkins M, Rezvani K, MD, PhD, Champlin RE, MD, Shpall EJ, MD, Neelapu SS, MD, Kebriaei P, MD, Ahmed S, MD. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). ASH 2020, 2020. e-Pub 2020.
69. Afrough A, MD, Alsfeld LC, MD, Srour SA, MD, MS, Bashir Q, MD, Saini N, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Delgado R, Murphy R, PA-C, Manasanch EE, MD, Lee HC, MD, Kaufman GP, MD, Patel KK, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. ASH 2020, 2020. e-Pub 2020.
70. Srour SA, MD, MS, Bashir Q, MD, Milton DR, MS, Nieto Y, MD, Mehta RS, MD, MPH, MS, Saini N, MD, Delgado R, Rondon G, Ciurea SO, MD, Popat UR, MD, Khouri IF, MD, Kebriaei P, MD, Manasanch EE, MD, Hosing C, MD, Patel KK, MD, Lee HC, MD, Shpall EJ, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. ASH 2020, 2020. e-Pub 2020.
71. Nieto Y, MD, Gruschkus SK, PhD, MPH, Jones RB, MD, PhD, Valdez BC, PhD, Timmons M, PA-C, Hosing C, MD, Anderlini P, Kebriaei P, MD, Popat UR, MD, Qazilbash MH, MD, Alousi AM, MD, Srour SA, MD, MS, Saini N, MD, Ramdial J, MD, Im JS, Shpall EJ, MD, Rezvani K, MD, PhD, Gulbis A, Shigle TL, PharmD, Mahadeo KM, MD, Khazal S, MD, Khouri IF, MD, Dabaja BS, MD, Pinnix CC, MD, PhD, Gunther JR, MD, PhD, Lee H, MD, Ahmed S, MD, Steiner RE, MD, Iyer SP, MD, Nair R, MD, Parmar S, MD, MSCI, Cuglievan B, MD, Maadani F, BS, MT, Rondon G, Champlin RE, MD, Andersson BS, MD, PhD. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. ASH 2020, 2020. e-Pub 2020.
72. Ramdial JL, MD, Ma J, MS, Milton DR, MS, Delgado R, Bashir Q, MD, Srour SA, MD, MS, Saini N, MD, Nieto Y, MD, Hosing C, MD, Popat UR, MD, Murphy R, PA-C, Lee HC, MD, Patel KK, MD, Manasanch EE, MD, Thomas SK, MD, Kaufman GP, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. ASH 2020, 2020. e-Pub 2020.
73. Andersson BS, MD, PhD, Thall P, Valdez BC, PhD, Ma J, MS, Chen J, Ahmed S, MD, Alousi AM, MD, Bashir Q, MD, Ciurea SO, MD, Gulbis A, Hosing C, MD, Jones RB, MD, PhD, Kawedia J, BPharm, Kebriaei P, MD, Kornblau SM, MD, Myers A, PharmD, PhD, RPh, Oran B, MD, MS, Rezvani K, MD, PhD, Shah N, MD, Shpall EJ, MD, Parmar S, MD, MSCI, Popat UR, MD, Nieto Y, MD, Champlin RE, MD. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. ASH 2020, 2020. e-Pub 2020.
74. Oran B, MD, MS, Ciurea SO, MD, Kebriaei P, MD, Mehta RS, MD, MPH, MS, Popat UR, MD, Hosing C, MD, McCarty JM, RN, Hindman B, PhD, Messahel B, MD, Champlin RE, MD. Safety, Tolerability and Efficacy of Crenolanib Administered Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with FLT3 Mutant AML. ASH 2020, 2020. e-Pub 2020.
75. Saini N, MD, Ma J, MS, Bashir Q, MD, Delgado R, Rondon G, Popat UR, MD, Hosing C, MD, Nieto Y, MD, Kebriaei P, MD, Alousi AM, MD, Mehta RS, MD, MPH, MS, Srour SA, MD, MS, Khouri IF, MD, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Patel KK, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. ASH 2020, 2020. e-Pub 2020.
76. Saini N, MD, Ma J, MS, Timmons M, PA-C, Alousi AM, MD, Anderlini P, Andersson BS, MD, PhD, Hosing C, MD, Ramdial J, MD, Kebriaei P, MD, Popat UR, MD, Qazilbash MH, MD, Shpall EJ, MD, Srour SA, MD, MS, Valdez BC, PhD, Dabaja BS, MD, Pinnix CC, MD, PhD, Gunther JR, MD, PhD, Maadani F, BS, MT, Rondon G, Champlin RE, MD, Nieto Y, MD. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). ASH 2020, 2020. e-Pub 2020.
77. Bachier C, MD, Borthakur G, MD, Hosing C, MD, Blum W, MD, Rotta M, MD, Ojeras P, Barnett B, MD, Rajangam K, MD, PhD, Majhail NS, MD, MS, Nikiforow S, MD, PhD. A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS). ASH 2020, 2020. e-Pub 2020.
78. Srour SA, MD, MS, Xu J, MD, Al-Juhaishi T, MD, Steiner RE, MD, Ensor J, PhD, Ahmed S, MD, Parmar S, MD, MSCI, Strati P, MD, Nastoupil LJ, MD, Nieto Y, MD, Hosing C, MD, Lee HJ, MD, Westin J, MD, Fowler NH, MD, Fayad L, Dabaja BS, MD, Pinnix CC, MD, PhD, Gunther JR, MD, PhD, Fang P, MD, Samaniego F, MD, Jain P, MBBS, MD, DM, PhD, Champlin RE, MD, Khouri IF, MD, Wang M, MD, Miranda RN, MD, Vega F, MD, PhD, Neelapu SS, MD, Flowers C, MD, MS, Iyer SP, MD. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. ASH 2020, 2020. e-Pub 2020.
79. Oran B, MD, MS, Alatrash G, Alousi AM, MD, Mehta RS, MD, MPH, MS, Hosing C, MD, Popat UR, MD, Im JS, McCarty JM, RN, Ramos JD, RN, Keer HN, MD, PhD, Thall PF, PhD, Champlin RE, MD. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. ASH 2020, 2020. e-Pub 2020.
80. Iyer SP, MD, Xu J, MD, Becnel MR, MD, Nair R, MD, Steiner R, MD, Feng L, MS, Lee HJ, MD, Strati P, MD, Ahmed S, MD, Parmar S, MD, MSCI, Nieto Y, MD, Hosing C, MD, Westin J, MD, Nastoupil LJ, MD, Vo A, Samaniego F, MD, Fowler NH, MD, Saini N, MD, Khouri IF, MD, Im JS, Jain P, MBBS, MD, DM, PhD, Fayad L, Wang M, MD, Miranda RN, MD, Vega F, MD, PhD, Flowers C, MD, MS, Neelapu SS, MD. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). ASH 2020, 2020. e-Pub 2020.
81. Srour SA, MD, MS, Nieto Y, MD, Iyer SP, MD, Miranda RN, MD, Maadani F, Rondon G, Saini N, MD, Strati P, MD, Daher M, Nair R, MD, Dabaja BS, MD, Popat UR, MD, Qazilbash MH, MD, Shpall EJ, MD, Flowers C, MD, MS, Champlin RE, MD, Hosing C, MD, Khouri IF, MD. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. ASH 2020, 2020. e-Pub 2020.
82. Mehta RS, MD, MPH, MS, Bassett R, Chen J, Valdez BC, PhD, Kawedia J, BPharm, Alousi AM, MD, Alatrash G, Bashir Q, MD, Ciurea S, MD, Hosing C, MD, Im JS, Kebriaei P, MD, Olson AL, Oran B, MD, MS, Qazilbash MH, MD, Srour SA, MD, MS, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD, Popat UR, MD. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. ASH 2020, 2020. e-Pub 2020.
83. Srour SA, MD, MS, Bashir Q, MD, Milton DR, MS, Nieto Y, MD, Mehta RS, MD, MPH, MS, Saini N, MD, Delgado R, Rondon G, Hosing C, MD, Ciurea SO, MD, Daher M, Popat UR, MD, Khouri IF, MD, Kebriaei P, MD, Manasanch EE, MD, Kaufman GP, MD, Patel KK, MD, Shpall EJ, MD, Lee HC, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. ASH 2020, 2020. e-Pub 2020.
84. Popat U, MD, Saliba RM, PhD, Rohtesh S Mehta MD, MPH, MS, Amanda Olson MD, Julianne Chen BS, Christina Ganesh BSN, RN, Glenda Woodworth BSN, RN, Becky McMullin BSN, RN, Amin M Alousi MD, Paolo Anderlini MD, Gheath Alatrash MD, Qaiser Bashir MD, Stefan O Ciuera MD, Chitra Hosing MD, Jin Seon Im MD, PhD, Partow Kebriaei MD, Issa F Khouri MD, David Marin MD, Richard E Champlin MD. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. BBMT 26(3):S125, 2020. e-Pub 2020.
85. Popat U, MD, Saliba RM, PhD, Mehta RS, MD, Olson AL, MD, Chen J, Ganesh C, BSN, RN, Rondon G, MD, Woodworth G, BSN, OCN, RN, McMullin B, Alousi AM, MD, Anderlini P, Alatrash G, DO, PhD, Bashir Q, MBBS, Ciurea SO, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Oran B, MD, MS, Saini N, MD, Srour S, Rezvani K, MD, PhD, Qazilbash MH, MD, Molldrem JJ, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. ASH 2019, 2019. e-Pub 2019.
86. Ciurea SO, MD, Varma A, MD, Kongtim P, MD, Srour S, Bashir Q, MBBS, Alousi AM, MD, Mehta RS, MD, Oran B, MD, MS, Popat U, MD, Hosing C, MD, Rondon G, MD, Chen J, Olson AL, MD, Konopleva MY, MD, PhD, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. ASH 2019, 2019. e-Pub 2019.
87. Olson AL, MD, Lin R, Bdaiwi M, MD, Thall PF, Rafei H, MD, Kaur I, PhD, Li L, MD, Abueg G, Timmons M, Chemaly R, MD, PhD, Marin D, MD, Alousi AM, MD, Ahmed S, MD, Ciurea SO, MD, Hosing C, MD, Kebriaei P, MD, Jones RB, PhD MD, Andersson BS, MD, PhD, Oran B, MD, MS, Abuddayeh A, Popat U, MD, Champlin RE, MD, Shpall EJ, MD, Rezvani K, MD, PhD. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. ASH 2019, 2019. e-Pub 2019.
88. Koller P, Saliba RM, PhD, Ledesma C, Rondon G, MD, Popat U, MD, Alousi AM, MD, Mehta RS, MD, Oran B, MD, MS, Olson AL, MD, Hosing C, MD, Qazilbash MH, MD, Khouri IF, MD, Ciurea SO, MD, Shpall EJ, MD, Jorgensen JL, MD, PhD, Wang SA, MD, Jain N, MD, Jabbour E, Kantarjian HM, MD, Champlin RE, Konopleva MY, MD, PhD, Kebriaei P, MD. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. ASH 2019, 2019. e-Pub 2019.
89. Popat U, MD, Mehta RS, MD, Bassett R, Olson AL, MD, Chen J, Ganesh C, BSN, RN, Alousi AM, MD, Anderlini P, Alatrash G, DO, PhD, Bashir Q, MBBS, Ciurea SO, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Oran B, MD, MS, Saini N, MD, Srour S, Rezvani K, MD, PhD, Qazilbash M, Molldrem JJ, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. ASH 2019, 2019. e-Pub 2019.
90. Aung FM, MD, Clancy N, BS, Lichtiger B, MD, PhD, Hosing C, MD. Optimizing the Use of Platelets in a Single Oncology Center during Critical Shortages: Can Current Platelet Donations from Volunteer Donors be Sustained to Provide Adequate Platelet Inventories Long Term?. ASH 2019, 2019. e-Pub 2019.
91. Iyer SP, MD, Neelapu SS, MD, Burns E, MD, Nair R, MBBS, MD, Hosing C, MD, Nieto Y, MD, PhD, Westin JR, MD, Parmar S, MBBS, Fowler NH, MD, Nastoupil LJ, MD, Duvic M, MD, Miranda RN, MD, Lee HJ, Samaniego F, MD, Ahmed S, MD, Lei F, MS, Huen A, MD. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). ASH 2019, 2019. e-Pub 2019.
92. Champlin RE, MD, Popat U, MD, Oran B, MD, MS, Ciurea SO, MD, Kebriaei P, MD, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MBBS, Khouri IF, MD, Hosing C, MD, Anderlini P, Jones RB, PhD MD, Marin D, MD, Mehta R, MD, Nieto Y, MD, PhD, Olson AL, MD, Qazilbash MH, MD, Rezvani K, MD, PhD, Shpall EJ, MD, Chen J, Rondon G, MD, McMullin B, Al Jahdhami VP, RN, Kawedia J, BPharm, Valdez BC, PhD, Ma J, MS, Thall PF, Andersson BS, MD, PhD. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. ASH 2019, 2019. e-Pub 2019.
93. Yalniz FF, Saliba RM, PhD, Yucel OK, Garcia-Manero G, MD, Ramdial J, MD, Popat U, MD, Ciurea SO, MD, Kebriaei P, MD, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MBBS, Hosing C, MD, Marin D, MD, Mehta R, MD, Olson AL, MD, Rezvani K, MD, PhD, Shpall EJ, MD, Rondon G, MD, Champlin RE, MD, Oran B, MD, MS. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. ASH 2019, 2019. e-Pub 2019.
94. Rafei H, Fernández-Viña M, Carmazzi Y, Moore B, Willis D, Basar R, Banerjee PP, Daher M, Hosing C, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Qazilbash MH, Shpall EJ, Champlin RE, Marin D, Rezvani K, Cao K. Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). ASCO 2019, 2019. e-Pub 2019.
95. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. ASCO 2019, 2019. e-Pub 2019.
96. Rafei H, Imahashi N, Basar R, Banerjee PP, Daher M, Ganesh C, Hosing C, Kaur I, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Spencer BP, Srour S, Shpall EJ, Champlin RE, Marin D, Rezvani K. Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. ASCO 2019, 2019. e-Pub 2019.
97. Saini NY, MD, Varma A, MD, Ma J, MS, Milton DR, Patel R, BA, Hasan O, Bashir Q, MBBS, Nieto Y, MD, PhD, Mukherjee A, MD, Delgado R, Rondon G, MD, Popat U, MD, Hosing C, MD, Kebriaei P, MD, Alousi AM, MD, Ahmed S, MD, Mehta RS, MD, MPH, MS, Ciurea SO, Khouri IF, Shpall EJ, MD, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, MSc, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. ASH 2018, 2018. e-Pub 2018.
98. Lin P, MD, PhD, Veltri LW, MD, Rezvani K, MD, PhD, Oran B, MD, MS, Ahmed S, MD, Alatrash G, DO, PhD, Mehta RS, MD, MPH, MS, Rondon G, MD, Kebriaei P, MD, Popat U, MD, Nieto Y, MD, PhD, Hosing C, MD, Jones RB, PhD MD, Qazilbash MH, MD, Khouri IF, Shpall EJ, MD, Champlin RE, MD, Marin D, MD. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. ASH 2018, 2018. e-Pub 2018.
99. Saini NY, MD, Saliba RM, PhD, Rondon G, MD, Maadani F, Popat U, MD, Oran B, MD, MS, Hosing C, MD, Bashir Q, MBBS, Olson AL, MD, Nieto Y, MD, PhD, Alousi AM, MD, Kebriaei P, MD, Srour SA, MD, Mehta RS, MD, MPH, MS, Anderlini P, MD, Shpall EJ, MD, Qazilbash MH, MD, Khouri IF, Fayad LE, Lee HJ, MD, Fowler NH, MD, Parmar S, MBBS, Westin JR, MD, Hagemeister F, MD, Champlin RE, MD, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. ASH 2018, 2018. e-Pub 2018.
100. Saini NY, MD, Patel R, BA, Varma A, MD, Bashir Q, MBBS, Hasan O, Delgado R, Rondon G, MD, Mukherjee A, MD, Popat U, MD, Hosing C, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Manasanch EE, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD, Patel KK, MD, MSc. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. ASH 2018, 2018. e-Pub 2018.
101. Patel R, BA, Saini NY, MD, Varma A, MD, Hasan O, Bashir Q, MBBS, Delgado R, Popat U, MD, Hosing C, MD, Mukherjee A, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Manasanch EE, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD, Patel KK, MD, MSc. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. ASH 2018, 2018. e-Pub 2018.
102. Daher M, Cao K, MS, MD, Basar R, MD, Marin D, MD, Sekine T, PhD, Rondon G, MD, Zhao W, MS, Smith NT, MS, Wang Q, BS, Li L, MD, Saliba RM, PhD, Kiran Pingali SR, MD, Popat U, MD, Hosing C, MD, Olson AL, MD, Oran B, MD, MS, Mehta RS, MD, MPH, MS, Champlin RE, MD, Shpall EJ, MD, Rezvani K, MD, PhD. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. ASH 2018, 2018. e-Pub 2018.
103. Dos Santos DMC, Saliba RM, PhD, Patel R, BA, Bashir Q, MBBS, Hosing C, MD, Kebriaei P, MD, Khouri IF, Nieto Y, MD, PhD, Popat U, MD, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, MSc, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
104. Saini NY, MD, Patel R, BA, Varma A, MD, Bashir Q, MBBS, Delgado R, Popat U, MD, Hosing C, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Alousi AM, MD, Ahmed S, MD, Mukherjee A, MD, Mehta RS, MD, MPH, MS, Khouri IF, Ciurea SO, Shpall EJ, MD, Hasan O, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, MSc, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. ASH 2018, 2018. e-Pub 2018.
105. Oran B, MD, MS, Lima MD, MD, Garcia-Manero G, MD, Thall PF, Lin R, Alousi AM, MD, Hosing C, MD, Kebriaei P, MD, Popat U, MD, Giralt S, MD, Ahmed S, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Bashir Q, MBBS, Ciurea SO, Rezvani K, MD, PhD, Woodworth G, BSN, OCN, RN, Champlin RE, MD. Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ASH 2018, 2018. e-Pub 2018.
106. Popat U, MD, Mehta RS, MD, MPH, MS, Bassett Jr RL, Olson AL, MD, Chen J, Ahmed S, MD, Alousi AM, MD, Anderlini P, MD, Alatrash G, DO, PhD, Bashir Q, MBBS, Ciurea SO, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Khouri IF, Marin D, MD, Nieto Y, MD, PhD, Oran B, MD, MS, Rezvani K, MD, PhD, Qazilbash MH, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. ASH 2018, 2018. e-Pub 2018.
107. Varma A, MD, Saini NY, MD, Sui D, Milton DR, Hasan O, Mukherjee A, MD, Bashir Q, MBBS, Rondon G, MD, Srour SA, MD, Popat U, MD, Hosing C, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Alousi AM, MD, Mehta RS, MD, MPH, MS, Khouri IF, Weber DM, MD, Thomas SK, MD, Manasanch EE, MD, Lee HC, MD, Patel KK, MD, MSc, Ciurea SO, Shpall EJ, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
108. Kongtim P, MD, Parmar S, MBBS, Milton DR, Ramos Perez JM, MD, Rondon G, MD, Chen J, Chilkulwar AR, Alatrash G, DO, PhD, Alousi AM, MD, Andersson BS, MD, PhD, Im JS, MD, PhD, Hosing C, MD, Bashir Q, MBBS, Khouri IF, Kebriaei P, MD, Oran B, MD, MS, Popat U, MD, Champlin RE, MD, Ciurea SO. Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes. ASH 2018, 2018. e-Pub 2018.
109. Ciurea SO, Borges Bittencourt MC, MD, Milton DR, Cao K, MS, MD, Kongtim P, MD, Rondon G, MD, Chen J, Konopleva MY, MD, PhD, Ramos Perez JM, Elshazly M, MD, MSc, Aljadayeh M, MD, Alvarez M, Im JS, MD, PhD, Alatrash G, DO, PhD, Mehta RS, MD, MPH, MS, Popat U, MD, Bashir Q, MBBS, Oran B, MD, MS, Hosing C, MD, Khouri IF, Kebriaei P, MD, Champlin RE, MD. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. ASH 2018, 2018. e-Pub 2018.
110. Gowda L, MD, Alijadayeh M, MD, Marin DC, MD, Ledesma C, Rondon G, MD, Popat U, MD, Alousi AM, MD, Oran B, MD, MS, Shah MV, MD, PhD, Ahmed S, MD, Kanagal-Shamanna R, MD, Ciurea SO, Shpall EJ, MD, Luthra R, Hosing C, MD, Qazilbash MH, MD, Rezvani K, MD, PhD, Jabbour EJ, MD, Patel KP, MBBS, PhD, Ravandi F, MBBS, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. ASH 2017, 2017. e-Pub 2017.
111. Gowda L, MD, Saliba RM, PhD, Shah MV, MD, PhD, Rondon G, MD, Badar I, MBBS, Olson AL, MD, Ciurea SO, Kebriaei P, MD, Srour SA, Parmar S, MBBS, Nieto Y, MD, PhD, Ahmed S, MD, Mehta RS, MD, MPH, MS, Alatrash G, DO, PhD, Marin DC, MD, Andersson BS, MD, PhD, Oran B, MD, MS, Bashir Q, MD, MBBS, Qazilbash MH, MD, Hosing C, MD, Khouri IF, Alousi AM, MD, Anderlini P, MD, Shpall EJ, MD, Rezvani K, MD, PhD, Champlin RE, MD, Popat U, MD. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. ASH 2017, 2017. e-Pub 2017.
112. Ciurea SO, Saliba RM, PhD, Chen J, Rondon G, MD, Popat U, MD, Parmar S, MBBS, Anderson B, Alousi AM, MD, Ahmed S, Bashir Q, MD, MBBS, Alatrash G, DO, PhD, Hosing C, Olson AL, MD, Mehta RS, MD, MPH, MS, Rezvani K, MD, PhD, Shpall EJ, MD, Khouri IF, Kebriaei P, MD, Champlin RE, MD. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. ASH 2017, 2017. e-Pub 2017.
113. Nieto Y, MD, PhD, Thall PF, Valdez BC, PhD, Ma J, MS, Timmons M, Trapp M, Ahmed S, MD, Shpall EJ, MD, Jones RB, PhD MD, Hosing C, MD, Anderlini P, Popat U, MD, Qazilbash MH, MD, Alousi A, MD, Gulbis AM, PharmD, Ledesma C, Champlin RE, MD, Andersson BS, PhD MD. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. ASH 2017, 2017. e-Pub 2017.
114. Kebriaei P, MD, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, Groot ED, Smith A, Yang Y, PhD, Rondon G, MD, Qazilbash MH, MD, Ciurea SO, Alousi AM, MD, Nieto Y, MD, PhD, Marin DC, MD, Popat U, MD, Hosing C, MD, Kantarjian HM, MD, Rezvani K, MD, PhD, Shpall EJ, MD, Champlin RE, MD, N Cooper LJ, MD, PhD, Singh H, MSc, PhD. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT). ASH 2017, 2017. e-Pub 2017.
115. Kongtim P, MD, Parmar S, MBBS, Milton DR, Rondon G, MD, Chen J, Oran B, MD, MS, Popat U, MD, Hosing C, Bashir Q, MD, MBBS, Kebriaei P, MD, Khouri IF, Champlin RE, MD, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. ASH 2017, 2017. e-Pub 2017.
116. Qazilbash MH, MD, Bashir Q, MD, Thall PF, Milton DR, Shah N, MD, Patel KK, MD, Andersson BS, MD, PhD, Nieto Y, MD, PhD, Kebriaei P, MD, Valdez BC, PhD, Kawedia J, BPharm, Parmar S, MBBS, Delgado R, Ahmed S, MD, Hosing C, MD, Popat U, MD, Shpall EJ, MD, Weber DM, MD, Thomas SK, MD, Manasanch EE, MD, Lee HC, MD, Orlowski RZ, MD, PhD, Champlin RE, MD. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASH 2017, 2017. e-Pub 2017.
117. Veltri LW, MD, Milton DR, Shah N, MD, Patel K, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Popat UR, MD, Parmar S, MD, Oran B, MD, Ciurea SO, MD, Hosing C, MD, Lee H, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Shpall EJ, MD, Champlin RE, MD, Qazilbash MH, MD, Bashir Q, MD. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
118. Shah N, MD, Thall PF, PhD, Milton DR, Bashir Q, MD, Parmar S, MD, Lin P, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Popat UR, MD, Hosing C, MD, Cornelison A, Delgado R, Shpall EJ, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash M, MD. Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. ASH 2016, 2016. e-Pub 2016.
119. Srour SA, MD, Khouri IF, MD, Lozano-Cerrada S, MD, Nieto Y, MD, PhD, Alousi AM, MD, Popat UR, MD, Qazilbash MH, MD, Anderlini P, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Hosing C, MD. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. ASH 2016, 2016. e-Pub 2016.
120. Kebriaei P, MD, Wei W, MS, Thall PF, PhD, Ledesma C, BS, Valdez BC, PhD, Popat UR, MD, Olson AL, MD, Alousi AM, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Marin D, MD, Rezvani K, MD, PhD, Nieto Y, MD, PhD, Champlin RE, MD, Andersson BS, MD, PhD. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. ASH 2016, 2016. e-Pub 2016.
121. Mohyuddin GR, MD, Faisal MS, MBBS, Shah N, MD, Bashir Q, MD, Hosing C, MD, Patel K, MD, Popat UR, MD, Parmar S, MD, Rondon G, MD, Delgado R, Weber DM, MD, Shah JJ, MD, Thomas S, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Champlin RE, MD, Qazilbash MH, MD. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. ASH 2016, 2016. e-Pub 2016.
122. Olson AL, MD, Muftuoglu M, MD, Kaur I, PhD, Li L, M, Abueg G, Chemaly RF, MD, MPH, Yvon E, PhD, Thall PF, PhD, Marin D, MD, Alousi AM, MD, Ahmed S, MD, Ciurea SO, MD, Hosing C, MD, Kebriaei P, MD, Jones R, MD, PhD, Andersson BS, MD, PhD, Shah N, MD, Oran B, MD, Abudayyeh A, Popat UR, MD, Champlin RE, MD, Shpall EJ, MD, Rezvani K, MD, PHD. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. ASH 2016, 2016. e-Pub 2016.
123. Bashir Q, MD, Shazly ME, Milton DR, Patel K, MD, Shah N, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Popat UR, MD, Parmar S, MD, Oran B, MD, Ciurea SO, MD, Hosing C, MD, Lee H, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Champlin RE, MD, Qazilbash M, MD. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. ASH 2016, 2016. e-Pub 2016.
124. Chen CE, MD, Mao AY, Murray JG, Oran B, MD, Qazilbash MH, MD, Shah N, MD, Ahmed S, MD, Bashir Q, MD, Hosing C, MD, Shpall EJ, MD, Steele JR, MD, Champlin RE, MD, Parmar S, MD. Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. ASH 2016, 2016. e-Pub 2016.
125. Cerrada SL, MD, Marin D, MD, Rondon G, MD, Ledesma C, BS, Popat UR, MD, Olson A, MD, Alousi A, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Rezvani K, MD, PhD, Jabbour E, MD, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. ASH 2016, 2016. e-Pub 2016.
126. Oran B, MD, Muftuoglu M, MD, Kaur I, PhD, Li L, MD, Yvon E, PhD, Abueg G, Bassett R, MS, Thall PF, PhD, Marin D, MD, Alousi AM, MD, Ahmed S, MD, Ciurea SO, MD, Nina S, MD, Hosing C, MD, Olson AL, MD, Parmar S, MD, Jones R, MD, PhD, Popat UR, MD, Andersson BS, MD, PhD, Champlin RE, MD, Shpall EJ, MD, Rezvani K, MD, PhD. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. ASH 2016, 2016. e-Pub 2016.
127. Ciurea SO, MD, Lee DA, MD, PhD, Denman C, MS, Schafer J, Bassett Jr RL, Cao K, MS, MD, Rondon G, MD, Chen J, Soebbing D, Willis DB, Ahmed S, MD, Bashir Q, MD, Kebriaei P, MD, Khouri IF, MD, Oran B, MD, Parmar S, MD, Popat UR, MD, Hosing C, MD, Yvon E, PhD, Rezvani K, MD, PhD, Shpall EJ, MD, Champlin RE, MD. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. ASH 2016, 2016. e-Pub 2016.
128. Hill L, MD, Saliba RM, PhD, Chen J, Rondon G, MD, Qazilbash MH, MD, Popat UR, MD, Shah N, MD, Neumann JL, APN, PhD, Hymes SR, MD, Hosing C, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Oran B, MD, Olson A, MD, Ciurea SO, MD, Rezvani K, MD, PhD, Marin D, MD, Champlin RE, MD, Shpall EJ, MD, Alousi AM, MD. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. ASH 2016, 2016. e-Pub 2016.
129. Aoki E, MD, PhD, Jain P, MBBS, MD, DM, PhD, Ferrajoli A, MD, Estrov Z, MD, Keating M, MBBS, O'Brien SM, MD, Wierda WG, MD, PhD, Jain N, MD, Thompson PA, MBBS, Jabbour E, MD, Pierce S, BSN, BA, Hosing C, MD, Kantarjian HM, MD, Ravandi F, MD, Kadia TM, MD. Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) – Single-Center Experience. ASH 2016, 2016. e-Pub 2016.
130. Cerrada SL, MD, Marin D, MD, Rondon G, MD, Ledesma C, BS, Popat UR, MD, Olson AL, MD, Alousi AM, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Rezvani K, MD, PhD, Jabbour E, MD, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. ASH 2016, 2016. e-Pub 2016.
131. Popat UR, MD, Lyons G, Bassett R, MS, Chen J, BS, Valdez BC, PhD, Kawedia JD, RPh, PhD, Ahmed S, MD, Alousi AM, MD, Anderlini P, MD, Bashier Q, Ciurea SO, MD, Hosing C, MD, Jones RB, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Marin D, Nieto Y, MD, PhD, Olson A, MD, Oran B, MD, Parmar S, MD, Patel K, MD, Qazilbash MH, MD, Rezvani K, MD, Shah N, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
132. Shah DP, MD, MSPH, PhD, Ghantoji SS, MD, MPH, Azzi J, Avadhanula V, Kmeid J, MD, Chaer FE, MD, Ariza-Heredia EJ, MD, Shah N, MD, Mulanovich VE, MD, Hosing C, MD, Piedra PA, MD, Chemaly RF, MD, MPH. An Open Label, Block-Randomized, Ribavirin Efficacy Trial for Management of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients: Clinical and Economic Implications. Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
133. Brammer JE, MD, Khouri IF, MD, Ledesma C, BS, Rondon G, MD, Ciurea SO, MD, Nieto Y, MD, PhD, Champlin RE, MD, Hosing C, MD, Kebriaei P, MD. T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL). Biol Blood Marrow Transplant 22(3), 2016. e-Pub 2016.
134. Valdez BC, PhD, Brammer JE, MD, Li Y, MS, Murray D, PhD, Teo EC, MD, Liu Y, Hosing C, MD, Nieto Y, MD, PhD, Champlin RE, MD, Andersson BS, MD, PhD. Romidepsin (Rom) Enhances the Cytotoxicity of Fludarabine (Flu), Clofarabine (Clo) and Busulfan (Bu) in Malignant T-Cells. Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
135. Sasaki K, MD, Bashir Q, MD, Shah N, MD, Hosing C, MD, Popat UR, MD, Nieto Y, MD, PhD, Parmar S, MD, Shah J, MD, Weber D, MD, Thomas S, MD, Orlowski RZ, MD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
136. Qazilbash MH, MD, Chen J, BS, Valdez BC, PhD, Sasaki K, MD, Kawedia JD, RPh, PhD, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Shah N, MD, Patel K, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD, Popat UR, MD. Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
137. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation 22(8), 2016. e-Pub 2016.
138. Nieto Y, MD, PhD, Bassett R, MS, Hosing C, MD, Jones RB, MD, PhD, Valdez BC, PhD, Kingham A, PA, Ahmed S, MD, Alousi AM, MD, Anderlini P, MD, Popat UR, MD, Qazilbash MH, MD, Shpall EJ, MD, Kebriaei P, MD, Brammer JE, MD, Oki Y, MD, Fanale MA, MD, Maadani F, BS, Rondon G, MD, Champlin RE, MD, Andersson BS, MD, PhD. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT). Biology of Blood and Marrow Transplantation 22(3), 2016. e-Pub 2016.
139. Chaer FE, Shah MD, MD, MSPH, PhD, Kmeid J, MD, Ariza-Heredia EJ, MD, Hosing C, MD, Chemaly RF, MD, MPH. Human Metapneumovirus (hMPV) Infections in 83 Hematopoietic Cell Transplant (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2016. e-Pub 2016.
140. Liu E, MD, MS, Tong Y, Dotti G, MD, Savoldo B, MD, Muftuoglu M, Kondo K, PhD, Mukherjee M, Orange JS, MD, PhD, Sobieski C, Alsuliman A, Shaim H, MD, Imahashi N, MD, PhD, Keating MJ, MD, Hosing CM, MD, Shah N, MD, Wierda W, MD, PhD, Champlin R, MD, Shpall EJ, MD, Rezvani K, PhD MD. Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity. ASH 2015, 2015. e-Pub 2015.
141. Alousi AM, MD, Bassett R, MS, Chen J, Overman BJ, BSN, Hosing CM, MD, Popat UR, MD, Shpall EJ, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Khouri IF, Kebriaei P, MD, Ahmed S, MD, Shah N, MD, Rezvani K, MD, PhD, Kondo K, PhD, Ciurea SO, MD, Hymes SR, MD, Neumann JL, APN, PhD, Molldrem JJ, MD, Plair TR, PA, Champlin RE, MD. Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. ASH 2015, 2015. e-Pub 2015.
142. Kebriaei P, MD, Ciurea SO, MD, Huls MH, BS, Singh H, PhD, Olivares S, BS, Su S, B, Figliola MJ, BS, Kumar P, PhD, Jena B, PhD, Forget M, PhD, Ang S, PhD, Jackson R, BS, Liu T, BS, McNiece IK, PhD, Rondon G, MD, Hackett P, PhD, Kantarjian HM, MD, Lee DA, MD, PhD, Popat UR, MD, Alousi A, MD, Oran B, MD, Shah N, MD, Hosing CM, M, Marin D, MD, Rezvani K, MD, PhD, Shpall EJ, MD, Champlin RE, MD. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. ASH 2015, 2015. e-Pub 2015.
143. Pingali SR, MD, Saliba R, Anderlini P, MD, Hosing CM, MD, Khouri IF, MD, Alousi AM, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Fanale MA, Shpall EJ, MD, Champlin RE, MD, Popat UR, MD. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. ASH 2015, 2015. e-Pub 2015.
144. Brammer JE, MD, Saliba RM, PhD, Jorgensen JL, MD, PhD, Ledesma C, Rondon G, MD, Poon M, Koh LP, Dibb W, BA, Fan G, MD, PhD, Saliba CK, Trainee C, Wang S, MD, Popat UR, MD, Shpall EJ, MD, Ravandi F, MD, Kantarjian H, MD, Maziarz RT, MD, Champlin RE, MD, Hosing CM, MD, Kebriaei P, MD. Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL). ASH 2015, 2015. e-Pub 2015.
145. Nieto Y, MD, PhD, Valdez BC, PhD, Thall PF, PhD, Wei W, MS, Jones R, MD, PhD, Hosing CM, MD, Ahmed S, MD, Popat UR, MD, Shpall EJ, MD, Qazilbash M, MD, Gulbis AM, Anderlini P, MD, Shah N, MD, Bashir Q, MD, Alousi AM, MD, Oki Y, MD, Hagemeister FB, MD, Champlin RE, MD, Andersson BS, MD, PhD. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. ASH 2015, 2015. e-Pub 2015.
146. Brammer JE, MD, Poon M, Koh LP, Caimi PF, MD, Lima MD, MD, Ledesma C, Dibb W, BA, Khouri IF, Oki Y, MD, Fanale MA, Champlin RE, MD, Maziarz RT, MD, Hosing CM, MD. Multi-Center Study of Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Extra-Nodal Natural Killer/T-Cell Lymphoma, Nasal Type (ENKL). ASH 2015, 2015. e-Pub 2015.
147. Gaballa S, MD, Ge I, El Fakih RO, MD, Brammer JE, MD, Wang SA, MD, Lee DA, MD, PhD, Petropoulos D, MD, Cao K, MS, MD, Rondon G, MD, Chen J, Hammerstrom AE, PharmD, BCOP, Al-Atrash G, MD, PhD, Korbling M, MD, Oran B, MD, Kebriaei P, MD, Ahmed S, MD, Shah N, MD, Rezvani K, PhD MD, Marin D, MD, Bashir Q, MD, Alousi AM, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Hosing CM, MD, Popat UR, MD, Shpall EJ, MD, Khouri IF, Champlin RE, MD, Ciurea SO, MD. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. ASH 2015, 2015. e-Pub 2015.
148. Sasaki K, MD, Shah N, MD, Bashir Q, MD, Hosing CM, MD, Popat UR, MD, Nieto Y, MD, PhD, Parmar S, MD, Shah JJ, MD, Weber D, MD, Weissinger D, Thomas SK, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. ASH 2015, 2015. e-Pub 2015.
149. Chihara D, MD, PhD, Fanale MA, Noorani M, Westin JR, MD, Nastoupil L, MD, Hagemeister FB, MD, Fayad LE, MD, Romaguera JE, MD, Samaniego F, MD, Turturro F, MD, Lee HJ, MD, Neelapu SS, MD, Rodriguez A, MD, Wang M, MD, Fowler N, MD, Miranda RN, MD, Hosing CM, MD, Nieto Y, MD, PhD, Davis RE, MD, Oki Y, MD. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. ASH 2015, 2015. e-Pub 2015.
150. Im JS, MD, PhD, Saliba RM, PhD, Abraham SC, MD, Ross W, MD, Rondon G, MD, Rashid A, MD, Shpall EJ, MD, Popat UR, MD, Qazilbash M, MD, Hosing CM, MD, Oran B, MD, Shah N, MD, Champlin RE, MD, Alousi AM, MD. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. ASH 2015, 2015. e-Pub 2015.
151. Locke FL, MD, Neelapu SS, MD, Bartlett NL, MD, Siddiqi T, MD, Chavez JC, MD, Hosing CM, MD, Ghobadi A, MD, Budde LE, MD, PhD, Navale L, MS, Aycock JS, BA, Wiezorek J, MD, MS, Go WY, MD, PhD. Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). ASH 2015, 2015. e-Pub 2015.
152. Popat UR, MD, Ray G, Bassett Jr RL, Poon MC, Valdez BC, PhD, Konoplev S, MD, PhD, Ahmed S, MD, Alousi AM, MD, Andersson B, MD, PhD, Bashir Q, MD, Ciurea SO, MD, Hosing CM, MD, Jones R, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Kim S, Nieto Y, MD, PhD, Olson AL, MD, Oran B, MD, Parmar S, MD, Qazilbash MH, MD, Rezvani K, MD, PHD, Shah N, MD, Shpall EJ, MD, Champlin RE, MD. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. ASH 2015, 2015. e-Pub 2015.
153. Chihara D, MD, PhD, Fanale MA, MD, Noorani M, Westin JR, MD, Nastoupil L, MD, Hagemeister FB, MD, Fayad LE, MD, Romaguera JE, MD, Samaniego F, MD, Turturro F, MD, Lee HJ, MD, Neelapu SS, MD, Rodriguez A, MD, Wang M, MD, Fowler N, MD, Miranda RN, MD, Hosing CM, MD, Nieto Y, MD, PhD, Davis RE, MD, Oki Y, MD. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. ASH 2015, 2015. e-Pub 2015.
154. Ragon BK, MD, Gulbis AM, Saliba RM, PhD, Chen J, Rondon G, MD, Popat UR, MD, Nieto Y, MD, PhD, Oran B, MD, Olson AL, MD, Patel K, MD, Hosing CM, MD, Qazilbash MH, MD, Shah N, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Alousi AM, MD. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH 2015, 2015. e-Pub 2015.
155. Kongtim P, MD, Popat UR, MD, Jimenez AM, MD, Gabella S, El Fakih RO, MD, Rondon G, MD, Chen J, Bueso-Ramos CE, MD, Borthakur G, MD, Pemmaraju N, Garcia-Manero G, MD, Kantarjian HM, MD, Alousi AM, MD, Hosing CM, MD, Anderlini P, MD, Khouri IF, Kebriaei P, MD, Andersson BS, MD, PhD, Oran B, MD, Rezvani K, MD, PhD, Marin D, MD, DM, MSc, Shpall EJ, MD, Champlin RE, MD, Ciurea SO, MD. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. ASH 2015, 2015. e-Pub 2015.
156. Shah N, MD, Li L, MD, Kaur I, PhD, McCarty J, Yvon E, PhD, Shaim H, MD, Muftuoglu M, Liu E, MD, MS, Sobieski C, Orlowski RZ, PhD, MD, Cooper LJ, MD, PhD, Lee DA, MD, PhD, Parmar S, MD, Cao K, MS, MD, Hosing CM, MD, Ahmed S, MD, Nieto Y, MD, PhD, Bashir Q, MD, Patel KK, Bollard CM, MD, McNiece IK, PhD, Qazilbash M, MD, Champlin RE, MD, Rezvani K, Shpall EJ, MD. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. ASH 2015, 2015. e-Pub 2015.
157. Kebriaei P, MD, Basset Jr RL, Ledesma C, Rondon G, MD, Oran B, MD, Ciurea SO, MD, Alousi AM, MD, Popat UR, MD, Patel KK, Ahmed S, MD, Olson AL, MD, Bashir Q, MD, Shah N, MD, Jones R, MD, PhD, Rezvani K, MD, PHD, Nieto Y, MD, PhD, Khouri IF, Qazilbash MH, MD, Hosing CM, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. ASH 2015, 2015. e-Pub 2015.
158. Shaim H, MD, Estrov Z, MD, Sekine T, Kondo K, PhD, Ruvolo PP, PhD, Thompson P, MBBS, Sarvaria A, MS, Muftuoglu M, Imahashi N, MD, PhD, Liu E, MD, MS, Sobieski C, Wierda W, MD, PhD, Keating MJ, MD, Shah N, MD, Hosing CM, MD, Alsuliman A, Basar R, MD, Ferrajoli A, MD, Shpall EJ, MD, Rezvani K, PhD MD. The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide. ASH 2015, 2015. e-Pub 2015.
159. Ramlal R, MD, Gaballa S, MD, Chen J, Rondon G, MD, Oran B, MD, Ahmed S, MD, Bashir Q, MD, Rezvani K, MD, PhD, Marin D, MD, Alousi AM, MD, Kebriaei P, MD, Qazilbash M, MD, Hosing C, MD, Popat UR, MD, Shpall EJ, MD, Champlin R, MD, Ciurea SO, MD. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. ASH 2015, 2015. e-Pub 2015.
160. Mehta RS, MD, MPH, MS, Saliba RM, PhD, Chen J, Rondon G, MD, Hammerstrom AE, PharmD, BCOP, Alousi AM, MD, Qazilbash MH, MD, Bashir Q, MD, Ahmed S, MD, Popat UR, MD, Hosing CM, MD, Khouri IF, Shpall EJ, MD, Champlin RE, MD, Ciurea SO, MD. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. ASH 2015, 2015. e-Pub 2015.
161. Nieto Y, MD, PhD, Bassett R, MS, Anderlini P, MD, Hosing CM, MD, Alousi AM, MD, Popat UR, MD, Andersson BS, MD, PhD, Valdez BC, PhD, Shpall EJ, MD, Ahmed S, MD, Qazilbash M, MD, Guillermo M, Oki Y, MD, Fanale MA, Hagemeister FB, MD, Dabaja BS, MD, Pinnix CC, PhD MD, Milgrom SA, MD, Tewari P, MD, Champlin RE, MD, Jones R, MD, PhD. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. ASH 2015, 2015. e-Pub 2015.
162. Rondon G, MD, Saliba RM, PhD, Chen J, Ledesma C, Alousi AM, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Khouri IF, Shpall EJ, MD, Popat UR, MD, Champlin RE, MD, Ciurea SO, MD. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2015, 2015. e-Pub 2015.
163. Chihara D, MD, PhD, Oki Y, MD, Westin JR, MD, Nastoupil L, MD, Fayad LE, MD, Samaniego F, MD, Wesson E, APN, Ruben C, BS, Horowitz SB, PharmD, Feng L, MS, Garg N, Ahmed S, MD, Khouri IF, Hosing CM, MD, Romaguera JE, MD, Fowler N, MD, Fanale MA, MD. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. ASH 2015, 2015. e-Pub 2015.
164. Mehta RS, MD, MPH, MS, Saliba RM, PhD, Cao K, MS, MD, Kaur I, PhD, Rezvani K, MD, PhD, Chen J, Olson A, Parmar S, MD, Shah N, MD, Marin D, MD, DM, MSc, Alousi AM, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Champlin RE, MD, McNiece IK, PhD, Lima MD, MD, Skerrett D, Burke E, Shpall EJ, MD, Oran B, MD. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. ASH 2015, 2015. e-Pub 2015.
165. Wang Y, MD, PhD, Wagner-Bartak N, MD, Zhou S, PhD, Fowler N, MD, Dela Rosa ML, Zhao D, MD, Romaguera JE, MD, Neelapu SS, MD, Hagemeister FB, MD, Fanale MA, MD, Oki Y, MD, Shah JJ, MD, Thomoas SK, MD, Hosing CM, MD, Zhang L, MD, PhD, Badillo M, Chen W, Cai Q, MD, PhD, Zou D, MD, PhD, Champlin RE, MD, Fayad LE, MD, Lee HJ, MD, Wang M, MD. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. ASH 2015, 2015. e-Pub 2015.
166. Brammer JE, Saliba R, Kantarjian H, Thomas D, Jorgensen JL, Gaballa S, Ledesma C, Popat UR, Shpall EJ, Champlin RE, Hosing C, Kebriaei P. Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease and Prognostic Factors at the MD Anderson Cancer Center. ASBMT 2015, 2015. e-Pub 2015.
167. Brammer JE, Khouri IF, Gaballa S, Ledesma C, Anderlini P, Andersson BS, Popat UR, Bashir Q, Hosing C, Champlin RE, Ciurea SO. Safety and Efficacy of Non-Myeloablative (NMA) Melphalan-Based Conditioning for Haploidentical Allogenic Stem Cell Transplantation (HaploSCT) in Patients with Advanced Lymphoma. ASBMT 2015, 2015. e-Pub 2015.
168. Gaballa S, Saliba R, Brammer JE, Lu G, Shah N, Bashir Q, Parmar S, Bock F, Hosing C, Popat UR, Delgado R, Rondon G, Shah J, Manasanch E, Orlowski RZ, Champlin RE, Qazilbash MH. Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience. ASBMT 2015, 2015. e-Pub 2015.
169. Popat UR, Saliba R, Oran B, Chen J, Alousi AM, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Nieto YL, Olson A, Parmar S, Shah N, Shpall EJ, Qazilbash MH, Andersson BS, Champlin RE. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. ASBMT 2015, 2015. e-Pub 2015.
170. Cornelison A, Saliba R, Ahmed S, Nieto YL, Bashir Q, Shah N, Parmar S, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Hematopoietic Stem Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) in the Inpatient (Inpt) Vs. Outpatient (Outpt) Settings: Impact of Hematopoietic Stem Cell Comorbidity Index (HCT-CI). ASBMT 2015, 2015. e-Pub 2015.
171. Thompson PA, Perera T, Marin D, Oran B, Popat UR, Qazilbash MH, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi AM, Ciurea SO, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie DS, Hosing C. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. ASBMT 2015, 2015. e-Pub 2015.
172. Hosing C, MD, Munsell M, Armitage S, Sadeghi T, Rezvani K, MD, Oran B, MD, Marin D, Dworsky S, Popat UR, MD, Wilson J, Alousi AM, MD, Shah N, MD, Olson A, MD, Jones RB, MD, PhD, Kebriaei P, MD, Qazilbash MH, MD, Parmar S, MD, McNiece I, PhD, Champlin RE, MD, Shpall EJ, MD. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. ASBMT 2015, 2015. e-Pub 2015.
173. Qazilbash MH, Thall P, Fox PS, Kebriaei P, Bashir Q, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Dinh Y, Hosing C, Popat UR, Lin P, Shah J, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASBMT 2015, 2015. e-Pub 2015.
174. Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat UR, Delgado R, Rondon G, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. ASBMT 2015, 2015. e-Pub 2015.
175. Baljevic M, Cao K, Champlin RE, Popat UR, Hosing C, Shah N, Parmar S, Rezvani K, Olson A, Shpall EJ, Oran B. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. ASBMT 2015, 2015. e-Pub 2015.
176. Badar T, MBBS, Parmar S, MD, Cornelison A, MS, PA-C, Shah N, MD, Bashir Q, MD, Patel K, MD, Hosing C, MD, Popat UR, MD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. ASBMT 2015, 2015. e-Pub 2015.
177. Laport GG, MD, Wu J, MS, Logan BR, PhD, Bachanova V, MD, Chitra M Hosing MD, Fenske TS, MD, Longo WL, MD, Devine SM, MD, Nademanee AP, MD, BS, Gersten I, MS, Horowitz MM, MD, MS, Lazarus HM, MD, Riches ML, MD, MS. Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701). Blood 124(21), 2014. e-Pub 2014.
178. Kebriaei P, Huls H, BS, Singh H, PhD, Olivares S, BS, Figliola M, BS, Maiti S, PHD, Shihuang S, PhD, Kumar PR, BS, Jena B, PhD, Forget MA, Ang S, PhD, Rineka J, BBA, Liu T, BS, McNiece IK, PhD, Rondon G, Hackett P, PhD, Wierda WG, MD, PhD, O'Brien S, MD, Keating MJ, MBBS, Kantarjian HM, MD, Hosing CM, MD, Shpall EJ, MD, Champlin RE, Cooper LJ, MD, PhD. Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood 124(21), 2014. e-Pub 2014.
179. Chemaly RF, Zakhem AE, Shah DP, Mori N, Nesher L, Ariza-Heredia E, Mulanovich VE, Kebriaei P, Hosing C, Rondon G. The Clinical Significance of Human Herpes Virus 6 (HHV-6) Dnaemia in 68 Hematopoietic Cell Transplant Recipients (HSCT). Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
180. Qazilbash MH, Thall P, Fox PS, Shah N, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto YL, Dinh Y, Popat UR, Hosing C, Lin P, Shpall EJ, Orlowski RZ, Champlin RE. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
181. Pingali SR, Milton D, di Stasi A, Patel RD, Kebriaei P, Popat UR, Alousi AM, Anderlini P, Qazilbash MH, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
182. Biritxinaga L, Jauch SF, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
183. Anderlini P, Saliba R, Ledesma C, Chancoco CM, Alexander TR, Alousi AM, Hosing C, Khouri IF, Nieto YL, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
184. Chu D, Valdez BC, Fox PS, Thall P, Worth L, Popat UR, Jones RB, Shpall EJ, Hosing C, Alousi AM, Rondon G, Kebriaei P, Champlin RE, Andersson BS. Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biology of Blood and Marrow Transplantation 20(2), 2014. e-Pub 2014.
185. Oran B, MD, Poon M, Chen J, Rondon G, MD, Ahmed S, MD, Andersson BS, MD, PhD, Bashir Q, MD, Ciurea SO, MD, Hosing CM, MD, Parmar S, MD, Qazilbash MH, MD, Popat UR, MD, Nieto Y, MD, PhD, Alousi A, MD, Jones RB, PhD MD, Rezvani K, MD, PhD, Lima MD, MD, Shpall EJ, MD, Champlin RE, MD, Kebriaei P, MD. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 21, 2013. e-Pub 2013.
186. Ahmed S, MD, Stasi AD, MD, Shpall EJ, MD, Khouri IF, MD, Alousi AM, MD, Ciurea SO, MD, Bashir Q, MD, Qazilbash M, MD, Jones RB, MD, PhD, Nieto Y, MD, PhD, Parmar S, MD, Kebriaei P, MD, Shah N, MD, Rezvani K, MD, PhD, Hosing CM, MD, Oran B, MD, Andreeff M, MD, PhD, Anderlini P, MD, Andersson BS, MD, PhD, Champlin RE, MD, Popat U, MD. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 122(21), 2013. e-Pub 2013.
187. Adekola KU, MD, Bashir Q, MD, Shah N, MD, Pingali SR, MD, Parmar S, MD, Popat UR, MD, Hosing CM, MD, Champlin RE, MD, Qazilbash MH, MD. Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. Blood 122(21), 2013. e-Pub 2013.
188. Benjamini O, MD, Rozovski U, MD, Jain P, MD, DM, PhD, Wierda WG, MD, O'Brien S, MD, Burger JA, MD, PhD, Ferrajoli A, MD, Faderl SH, MD, Shpall EJ, MD, Hosing CM, MD, Khouri IF, MD, Champlin RE, MD, Keating MJ, MD, Estrov Z, MD. Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. Blood 122(21), 2013. e-Pub 2013.
189. Y Cruz CR, MD, PhD, Micklethwaite KP, MD, PhD, Savoldo B, MD, PhD, Ramos CA, MD, Lam S, BS, Ku S, BS, Diouf O, BS, Liu E, MD, MS, Barrett A, MD, FRCP, FRCPath, Ito S, Shpall EJ, MD, Krance RA, MD, Kamble RT, MD, Carrum G, MD, Hosing CM, MD, Gee AP, PhD, Mei Z, MD, Grilley BJ, RPh, Heslop HE, MD, Rooney CM, PhD, Brenner MK, MD, PhD, Bollard CM, MBChB, MD, Dotti G, MD. Infusion Of Donor-Derived CD19-Redirected-Virus-Specific T Cells For B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase I Study. Blood 122(21), 2013. e-Pub 2013.
190. Daver N, MD, Kantarjian HM, MD, Faderl SH, MD, Garcia-Manero G, MD, O'Brien S, MD, Ferrajoli A, MD, Verstovsek S, MD, PhD, Popat U, MD, Hosing CM, MD, Kadia TM, MD, Cortes JE, MD, Ravandi F, MD, Anderlini P, MD. Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. Blood 122(21), 2013. e-Pub 2013.
191. Pingali SR, MD, Denai M, M S, Stasi AD, MD, Kebriaei P, MD, Popat UR, MD, Alousi A, MD, Anderlini P, MD, Parmar S, MD, Hosing CM, MD, Andersson BS, MD, PhD, Bashir Q, MD, Ahmed S, MD, Oran B, MD, Shpall EJ, MD, Khouri I, MD, Konopleva M, MD, PhD, Alatrash G, DO, PhD, Champlin RE, MD, Ciurea SO, MD. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 122(21), 2013. e-Pub 2013.
192. Kebriaei P, MD, Huls H, BS, Singh H, PhD, Olivares S, BS, Figliola M, BS, Kumar PR, BS, Jena B, PhD, Forget MA, Ang S, PhD, Jackson RN, BBA, Liu T, BS, Bosque D, ADN, McNiece IK, PhD, Rondon G, MD, Hackett P, PhD, Hosing CM, MD, Shpall EJ, MD, Champlin RE, MD, N Cooper LJ, MD, PhD. First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood 122(21), 2013. e-Pub 2013.
193. Anderlini P, MD, Saliba RM, PhD, Ledesma C, BS, Chancoco CM, Alexander T, PA, Alousi A, MD, Hosing CM, MD, Khouri I, MD, Nieto Y, MD, PhD, Popat UR, MD, Shpall EJ, MD, Fanale MA, MD, Oki Y, MD, Romaguera JE, MD, Neelapu S, MD, Younes A, MD, E Champlin AR, MD. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood 122(21), 2013. e-Pub 2013.
194. Schuster SJ, MD, Hosing CM, MD, Shpall EJ, MD, Levine BL, PhD, Aqui NA, MD, Chong EA, MD, Svoboda J, MD, Bosque D, ADN, Cotte J, Zheng Z, Kaur I, PhD, Veloso E, JD, BSN, Bollard CM, MBChB, MD, Keating MJ, MD, June CH, MD. Adoptive Immunotherapy With Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy In Patients With Chronic Lymphocytic Leukemia. Blood 122(21), 2013. e-Pub 2013.
195. Pingali SR, MD, Saliba RM, PhD, Smith VR, APN, Maadani F, Adekola KU, MBBS, Popat UR, MD, Qazilbash MH, MD, Bashir Q, MD, Khouri I, MD, Kebriaei P, MD, Ciurea SO, MD, Anderlini P, MD, Shah N, MD, Nieto Y, MD, PhD, Champlin RE, MD, Hosing CM, MD. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood 122(21), 2013. e-Pub 2013.
196. Khouri IF, MD, Wei W, MS, Valverde R, MD, Korbling M, MD, Turturro F, MD, Gulbis AM, PharmD, BCOP, Guillermo-Pacheco M, Ahmed S, MD, Alousi A, MD, Oran B, MD, Anderlini P, MD, Ciurea SO, MD, Hosing CM, MD, Popat UR, MD, Jabbour E, MD, Champlin RE, MD, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 122(12), 2013. e-Pub 2013.
197. Nieto Y, MD, PhD, Thall PF, PhD, Valdez BC, PhD, Hosing CM, MD, Ahmed S, MD, Jones RB, PhD MD, Shah N, MD, Anderlini P, MD, Qazilbash MH, MD, Popat UR, MD, Bashir Q, MD, Shpall EJ, MD, Alousi A, MD, Kebriaei P, MD, Fox P, MS, Bassett R, MS, Chancoco C, Oki Y, MD, Fanale MA, MD, Fowler N, MD, Hagemeister F, MD, Romaguera JE, MD, Champlin RE, MD, Andersson BS, MD, PhD. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood 122(21), 2013. e-Pub 2013.
198. Stasi AD, MD, Poon LM, MD, Ferro R, MD, Milton D, Rondon G, MD, Wang SA, MD, Hamdi A, MD, Qazilbash MH, MD, Ahmed S, MD, Khouri I, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Alousi A, MD, Popat UR, MD, Shpall EJ, MD, Lee DA, MD, PhD, Rezvani K, MD, PhD, Champlin RE, MD, Ciurea SO, MD. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 122(21), 2013. e-Pub 2013.
199. Khouri IF, MD, Saliba RM, PhD, Xu-Monette ZY, MD, Rondon G, MD, Valverde R, MD, Korbling M, MD, Gulbis AM, PharmD, BCOP, Anderlini P, MD, Sairah A, MD, Hosing CM, MD, Popat UR, MD, Kebriaei P, MD, Fayad LE, Westin JR, MD, Turturro F, MD, Medeiros L, MD, Champlin RE, MD, Young KH, MD, PhD. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood 122(21), 2013. e-Pub 2013.
200. Popat UR, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Rezvani K, MD, PhD, Parmar S, MD, Shah N, MD, Bollard CM, MBChB, MD, Molldrem JJ, MD, Nieto Y, MD, PhD, Andersson BS, MD, PhD, Alousi A, MD, Jones RB, MD, PhD, N Cooper LJ, MD, PhD, Qazilbash MH, MD, Bashir Q, MD, Ahmed S, MD, Bosque D, ADN, Chen J, McCarty J, Rondon G, MD, Munsell M, McNiece IK, PhD, Kaur I, PhD, Yvon E, PhD, Annandale K, Olchesky S, de Lima MJ, MD, Champlin RE, MD, Miller L, PhD, Paradiso L, DVMMBA, Koh L, MS, MBA, Zweidler-McKay PA, MD/PhD, Shpall EJ, MD. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 122(21), 2013. e-Pub 2013.
201. Khouri IF, MD, Saliba RM, PhD, Challagundla P, Ledesma C, Korbling M, MD, Gulbis AM, PharmD, BCOP, Guillermo-Pacheco M, Ahmed S, MD, Anderlini P, MD, Bashir Q, MD, Oran B, MD, Ciurea SO, MD, Hosing CM, MD, Kebriaei P, MD, Popat UR, MD, Jabbour E, MD, Champlin RE, MD, Jorgensen JL, MD, PhD. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 122(21), 2013. e-Pub 2013.
202. j L, Smith VR, Sorensen S, Samaniego C, Huong T, Korbling M, Mercado G, Hosing C. Amicus Cell Separator for Stem cell collection: Relative Platelet Sparing with Acceptable Stem cell Yield. J Clin Apheresis 28(2):97, 2013. e-Pub 2013.
203. Cornelison A, Dinh Y, Ahmed S, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shah J, Shpall E, Champlin R, Qazilbash M. Younger (<50 years) multiple myeloma (MM) patients (pts) treated with novel agents and autologous haematopoietic stem cell transplantation (auto-HCT) have longer overall survival than older pts (>50 years). Bone Marrow Transplantation 48(S2):S205, 2013. e-Pub 2013.
204. Ahmed S, Saliba RM, Lima MD, Rondon G, Kebriaei P, Fisher TD, Jabbour E, Chen J, Kantarjian H, Anderlini P, Alousi AM, Hosing CM, Andersson B, Jones RB, Qazilbash MH, Shpall EJ, Giralt S, E Champlin AR. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Blood 120(21):1997, 2012. e-Pub 2012.
205. Patel K, Saliba RM, Shah N, Bashir Q, Thomas SK, Dinh YT, Hosing CM, Popat UR, Parmar S, Giralt SA, Champlin RE, H Qazilbash AM. Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. Blood 120(21):abstract #4533, 2012. e-Pub 2012.
206. Khouri IF, Rima SM, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, E Champlin AR. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood 120(21):abstract #4157, 2012. e-Pub 2012.
207. Hamdi A, Poon LM, Saliba RM, Rondon G, Ledesma C, Qazilbash M, Hosing CM, Jones RB, Popat UR, Nieto, Alousi AM, Ciurea SO, Shpall EJ, Champlin RE, Kebriaei AP. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 120(21):abstract #4215, 2012. e-Pub 2012.
208. Gul Z, Bashir Q, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, H Qazilbash AM. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 120(21):abstract #2027, 2012. e-Pub 2012.
209. Alousi AM, Saliba RM, Chen J, Andersson BS, Khouri I, Qazilbash MH, Popat UR, Hosing CM, Ciurea SO, Shpall EJ, Jones RB, Kebriaei P, Nieto Y, Anderlini P, DeLima M, Rondon G, E Champlin AR. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood 120(21):abstract #4157, 2012. e-Pub 2012.
210. Lima MD, Parmar S, Chen JJ, Giralt SA, Rondon G, Popat UR, Alousi AM, Lee HC, Woodworth GG, Hosing CM, Shpall EJ, Kebriaei P, Manero GG, Champlin RE, M Saliba AR. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 120(21):abstract #742, 2012. e-Pub 2012.
211. Khan D, Patel K, Thomas SK, Weber DM, Delasalle KB, Hosing CM, Popat UR, Bashir Q, Shah N, Parmar S, Champlin RE, Qazilbash AM. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia. Blood 120(21):abstract #4128, 2012. e-Pub 2012.
212. Gul Z, Khan H, Bashir Q, Shah N, Parmar S, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Anderlini P, Shpall EJ, Giralt S, Champlin RE, H Qazilbash AM. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. Blood 120(21):abstract #3094, 2012. e-Pub 2012.
213. Aung FM, Lichtiger B, Reddy V, Hosing C. Use of granulocytes concentrates from a single high yield apheresis to support more than one patient. J Clin Oncol 30, 2012. e-Pub 2012.
214. Najera JE, Sudhakar T, Bashir Q, Shah N, Champlin RE, Qazilbash MH, Giralt S, Hosing C, Popat UR, Ciurea SO. Neurotoxicity after high-dose melphalan. J Clin Oncol 30, 2012. e-Pub 2012.
215. Sasaki K, Lu G, Hosing C, Popat UR, Ahmed S, Shah N, Bashir Q, Dinh Y, Orlowski RZ, Champlin RE, Qazilbash M. Impact of t (11; 14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma. J Clin Oncol 30, 2012. e-Pub 2012.
216. Chiattone A, Saliba R, Chiattone V, Tang X, Hamerschlak N, Maadani F, Qazilbash MH, Popat U, Kebriaei P, Champlin R, Hosing C, Lima MD. Determinants of higher pre-apheresis CD34+ count in patients undergoing autologous haematopoietic stem cell mobilization. Bone Marrow Transplantation 47, 2012. e-Pub 2012.
217. Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja B, Champlin R, Duvic M. Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sézary syndrome. Bone Marrow Transplantation 47, 2012. e-Pub 2012.
218. Bollard C, Cruz C, Savoldo B, Krance R, Kamble R, Barrett A, Hosing C, Shpall E, Heslop H, Leen A, Rooney C, Brenner M, Dotti G. Outcomes of CD19-directed multivirus specific cytotoxic T lymphocyte therapy for patients with relapsed B cell malignancies after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation 47, 2012. e-Pub 2012.
219. Tran HT, Mercado GY, Hosing CM, Smith VR, Samaniego C, Lastimoso JY, Douglas Z. Study Comparing The Efficiency of UVAR™-XTS™ System to the CELLEX™ System for Extracorporeal Photopheresis. J Clin Apheresis 27, 2012. e-Pub 2012.
220. Nieto Y, Jones RB, Popat U, Andersson B, Valdez B, Thall P, Shpall EJ, Chancoco C, Alousi A, Anderlini P, Hosing C, Qazilbash M, Bashir Q, Kebriaei P, Khouri I, Ciurea, Parmar S, Rondon G, Champlin R. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin's Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT). Biology of blood and Marrow Transplantation 18:S206, 2012. e-Pub 2012.
221. Nieto Y, Jones RB, Liu P, Anderlini P, Popat U, Andersson B, Shpall EJ, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Chancoco C, Bashir Q, Ciurea S, Parmar S, Champlin R. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin's Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant. Biology of Blood and Marrow Transplantation:S206-S207, 2012. e-Pub 2012.
222. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing C, Popat U, Parmar S, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. Outcome of Patients with Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 18:S248-S249, 2012. e-Pub 2012.
223. Lima MD, Ahmed S, Shpall EJ, Rondon G, Chen J, Woodworth GG, Chiattone A, Chu DT, Popat UR, Campos SR, Alousi AM, Hosing CM, Parmar S, Kebriaei P, Khouri IF, Cortes JE, Issa JJ, Champlin AR. Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood 118(21), 2011. e-Pub 2011.
224. Zipp L, Saliba RM, Valverde R, Okoroji G, Korbling M, Samuels BI, Abruzzo LV, Alousi AM, Andersson BS, Hosing CM, Erwin B, Anderlini P, Popat UR, Kebriaei P, Macapinlac HA, Champlin R, F Khouri AI. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies. Blood 118(21), 2011. e-Pub 2011.
225. Saliba RM, Chiattone A, Majlis A, Chiattone VC, Rondon G, Sakashita AM, Hamerschlak N, Kutner JM, Shpall EJ, Anderlini P, Khouri I, Qazilbash MH, Popat U, Champlin R, Hosing CM, De Lima AM. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,. Blood 118(21), 2011. e-Pub 2011.
226. Parmar S, Rondon G, Thall PF, Bassett R, Lima MD, Hosing CM, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Efebera YA, Champlin R, A Giralt AS. Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens. Blood 118(21), 2011. e-Pub 2011.
227. Chakhachiro ZI, Saliba RM, Okoroji G, Korbling M, Alousi AM, Hosing CM, Lima MD, Anderlini P, Popat U, Samuels BI, Medeiros L, Bueso-Ramos CE, Champlin R, F Khouri AI. 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years. Blood 118(21), 2011. e-Pub 2011.
228. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Acholonu S, Valverde R, Popat UR, Hosing CM, Alousi AM, Shpall EJ, Nieto Y, Ciurea SO, Khouri I, Champlin AR. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). Blood 118(21), 2011. e-Pub 2011.
229. Popat U, Andersson BS, Bassett R, Ciurea S, Rondon G, Alousi AM, Anderlini P, Hosing C, Jones R, Kebriaei P, Nieto Y, Khouri I, Shpall EJ, Verstovsek S, Qazilbash M, de Lima MJ, Champlin AR. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood 118(21), 2011. e-Pub 2011.
230. Anguita T, Chiattone A, Hamerschlak N, Saliba RM, Tang X, Wu D, Majilis A, Sakashita AM, Chiattone VC, Barros JC, Chiattone CS, Kutner JM, Rodrigues M, Kondo AT, Okoroji G, do Nascimento CMB, Fernandes JF, Popat U, Champlin RE, Anderlini P, Lima MD, M Hosing AC. Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. Blood 118(21), 2011. e-Pub 2011.
231. Beitinjaneh A, Saliba RM, Okoroji G, Korbling M, Alousi AM, Popat U, Anderlini P, Bashir Q, Andersson BS, Kebriaei P, Hosing CM, Qazilbash M, Fanale MA, Pro B, Champlin R, Khouri AI. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. Blood 118(21), 2011. e-Pub 2011.
232. Anderlini P, Acholonu S, Okoroji G, Giralt SA, Jones R, Hosing CM, Qazilbash MH, Nieto Y, Andersson BS, Popat UR, Ueno NT, de Lima MJ, E Champlin AR. Donor Leukocyte Infusions (DLIs) for Recurrent Hodgkin Lymphoma (HL) Following Allogeneic Stem Cell Transplantation (allo-SCT): Ten-Year Experience at the M.D. Anderson Cancer Center. Blood 118(21), 2011. e-Pub 2011.
233. Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, Lima MD, Champlin R, Giralt AS. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma,. Blood 118(21), 2011. e-Pub 2011.
234. Popat U, Bassett R, Padua Silva LD, Alousi AM, Anderlini P, Hosing CM, Jones R, Kebriaei P, Khouri I, Shpall EJ, Qazilbash MH, Garcia-Manero G, Andersson BS, Champlin R, de Lima AMJ. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. Blood 118(21), 2011. e-Pub 2011.
235. Xing D, Ramsay AG, Decker W, Lee DA, Robinson S, Shah N, Parmar S, Bollard CM, Hosing CM, Champlin R, Gribben JG, J Shpall AE. CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood 118(21), 2011. e-Pub 2011.
236. Ahmed S, Lin H, Baladandayuthapani V, Khan MA, Lu G, Rondon G, Qureshi S, Dinh YT, Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Champlin R, H Qazilbash AM. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118(21), 2011. e-Pub 2011.
237. Zhou Y, Jorgensen JL, Saliba RM, Wang SA, Rondon G, Ledesma C, Andersson BS, de Lima MJ, Shpall EJ, Popat U, Ciurea SO, Alousi AM, Qazilbash M, Hosing CM, Medeiros L, Champlin R, Kebriaei AP. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood 118(21), 2011. e-Pub 2011.
238. Schuster SJ, Hosing CM, Shpall EJ, Levine BL, Aqui NA, Chong EA, Svoboda J, Gordon A, McMannis JD, Bosque D, Cotte J, Brennan AL, Zheng Z, Leinbach L, Xu Y, Veloso E, Decker W, Bollard CM, Keating MJ, H June AC. Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood 118(21), 2011. e-Pub 2011.
239. Ciurea SO, Saliba RM, Bayraktar UD, Xie S, Rondon G, Parmar S, Kebriaei P, Montes N, Sharma M, Konopleva M, Nieto Y, Qazilbash MH, Alousi AM, Andersson BS, Hosing CM, Shpall EJ, Khouri IF, Lima MD, Champlin AR. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). Blood 118(21), 2011. e-Pub 2011.
240. Chiattone A, Saliba RM, Chiattone VC, Tang X, Hamerschlak N, Maadani F, Qazilbash MH, Popat U, Kebriaei P, Champlin R, Hosing CM, DeLima AM. Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization. Blood 118(21), 2011. e-Pub 2011.
241. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing CM, Popat U, Parmar S, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, H Qazilbash AM. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. Blood 118(21), 2011. e-Pub 2011.
242. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, H Qazilbash AM. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 118(21), 2011. e-Pub 2011.
243. Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin AR. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study. Blood 118(21), 2011. e-Pub 2011.
244. Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, Lima MD, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, A Macapinlac AH. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood 118(21), 2011. e-Pub 2011.
245. Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones AR. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood 118(21), 2011. e-Pub 2011.
246. Ciurea S, Saliba R, Rondon G, Sharma M, Montes N, Bosque D, McMannis J, Fernandez-Vina M, Xie S, Konopleva M, Parmar S, Nieto Y, Kebriaei P, Qazilbash M, Alousi A, Popat U, Hosing C, Shpall E, Khouri I, de Lima M, Champlin R. Haploidentical Stem Cell Transplantation for Minorities. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S227, 2011. e-Pub 2011.
247. Yilmaz M, Han X, de Lima M, Hosing C, Popat U, Champlin R, Qazilbash M. Incidence and Outcome of Adenovirus Infection in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S290, 2011. e-Pub 2011.
248. Beitinjaneh A, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin R, Giralt S, Qazilbash M. Donor-Lymphocyte Infusion in Patients with Persistent or Recurrent Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S340, 2011. e-Pub 2011.
249. Andersson B, Valdez B, Thall P, Wang X, Worth L, Popat U, Alousi A, Hosing C, Jones R, Shpall E, de Lima M, Champlin R. Clofarabine + Fludarabine and IV Busulfan with Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S293, 2011. e-Pub 2011.
250. Bear A, Hanley P, Bosque D, de Lima M, Kebriaei P, Hosing C, Heslop H, Bollard C. Immediate Adverse Events Following Infusion of Ex Vivo-Expanded Cord Blood for Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S312, 2011. e-Pub 2011.
251. Aung F, Lichtiger B, Alousi A, Hosing C, Qazilbash M, de Lima M, Kebriaei P, Khouri I, Champlin R, Popat U. The Incidence and Natural History of Pure Red Cell Aplasia In Major Abo Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S153, 2011. e-Pub 2011.
252. Trevino C, Westmoreland M, Hosing C. Use of Topical Cidofovir for the Treatment of Resistant Herpes Simplex Viral Infections in Post Allogeneic Hematopoietic Stem Cell Transplant Patients: Two Case Reports. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S363, 2011. e-Pub 2011.
253. Smith V, Tran H, Dinh Y, Guillermo-Pacheco M, Rondon G, Hosing C. Retrospective Study to Define the Ultimate Timing For Starting Stem Cell Collection in the Autologous Setting and To compare Engraftment Data of Patients who Achieve Target Dose in Greater than 4 Versus Less Than 4 Collections. Biology of Blood and Marrow Transplantation 17(2, Supplement 2):S361, 2011. e-Pub 2011.
254. Chiattone A, Saliba R, Andersson B, Giralt S, Sharma M, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Al-Atrash G, Bashir Q, Chem J, Yuen C, Chiattone V, Champlin R, de Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood 116(21):1413, 2010. e-Pub 2010.
255. Sharma M, Saliba R, Qazilbash M, Okoroji G, Popat U, de Lima M, Champlin R, Hosing C. Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes in Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. Blood 116(21):566, 2010. e-Pub 2010.
256. Nieto Y, Anderlini P, Popat U, Liu P, Andersson B, Shpall E, Kebriaei P, Hosing C, Alousi A, Qazilbash M, Ciurea S, Parmar S, Champlin R, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood 116(21):304, 2010. e-Pub 2010.
257. Okoroji G, de Padua Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri I. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood 116(21):1442, 2010. e-Pub 2010.
258. de Lima M, Robinson S, McMannis J, Alousi A, Saliba R, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Kelly S, Rondon G, Fernandez-Vina M, Maewal I, Bosque D, Bollard C, Chen J, McNiece I, Komanduri K, Nieto Y, Jones R, Andersson B, Popat U, Champlin R, Simmons P, Shpall E. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood 116(21):164, 2010. e-Pub 2010.
259. Alousi A, Andersson B, Saliba R, Botnick W, Rondon G, Shpall E, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash M, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood 116(21):967, 2010. e-Pub 2010.
260. Ciurea S, Aung F, de Lima M, Thall P, Rondon G, Kebriaei P, Alousi A, Shpall E, Hosing C, Khouri I, Champlin R, Fernandez-Vina M. Anti-HLA Antibodies and Graft Rejection in Hematopoietic Stem Cell Transplantation. Blood 116(21):229, 2010. e-Pub 2010.
261. Pozadzides J, Perini G, Hess M, Romaguera J, Hagemeister F, McLaughlin P, Fayad L, Khouri I, Hosing C, Pro B. Prognosis and treatment of patients with peripheral T-cell lymphoma: the M. D. Anderson Cancer Center experience. Journal of Clinical Oncology 28(15S):585s, 2010. e-Pub 2010.
262. Bashir Q, Andersson B, De Padua Silva L, Rondon G, Chiattone A, Hosing C, Fernandez-Vina M, Giralt S, Champlin R, De Lima M. Treatment of acute myeloid leukemia (AML0 in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT). Journal of Clinical Oncology 28(15S):495s, 2010. e-Pub 2010.
263. Shah N, Ahmed K, Qureshi S, Shah J, Orlowski R, Weber D, Hosing C, Popat U, Alousi A, Champlin R, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 114(22):506, 2009. e-Pub 2009.
264. Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash M, Jones R, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood 114(22):900, 2009. e-Pub 2009.
265. Alousi A, Rondon G, Okoroji G, Popat U, De Padua Silva L, Hymes S, Neumann J, Brunelle N, Kebriaei P, Hosing C, Khouri I, Shpall E, Qazilbash M, Giralt, Champlin R, Saliba R. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood 114(22):884, 2009. e-Pub 2009.
266. Rotem-Yehudar R, Armand P, Devine S, Fay J, Hosing C, Mapara M, Campagnero E, Uberti J, Avigan D, Ballen K, Winter J, Nagler A, Gordon L. The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT). Blood 114(22):500, 2009. e-Pub 2009.
267. Popat U, Hosing C, Fanale M, Medeiros LJ, Alousi A, Giralt S, de Lima M, Qazilbash M, Kebriaei P, Younes A, Khouri I, Andersson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood 114(22):912, 2009. e-Pub 2009.
268. Kebriaei P, Madden T, Kazerooni R, Shpall E, Wang X, Thall P, Hosing C, Qazilbash M, Popat U, Ledesma C, Khouri I, Champlin R, Jones R, Andersson B. Intravenous Busulfan Plus Melphalan is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. Blood 114(22):3415, 2009. e-Pub 2009.
269. Bashir Q, Thall P, Hosing C, Mendoza F, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin R, Giralt S, Qazilbash M. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood 114(22):487, 2009. e-Pub 2009.
270. De Padua Silva L, Saliba R, McCormick D, Okoroji G, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, Khouri I. Autologous Stem Cell Mobilization with Cytokines and in-Vivo alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood 114(22):1245, 2009. e-Pub 2009.
271. Daulat S, Talpur R, Hosing C, Duvic M. Long-Term Complete Responses to Combination Therapies in Sezary Patients. Blood 114(22):1308, 2009. e-Pub 2009.
272. Sharma M, Thall P, Wang X, Hosing C, Mendoza F, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin R, Giralt S, Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 114(22):912, 2009. e-Pub 2009.
273. Khouri I, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett R, Amin A, Anderlini P, de Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak A, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan (90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood 114(22):357, 2009. e-Pub 2009.
274. de Lima M, McMannis J, Hosing C, Kebriaei P, Robinson S, Kelly S, de Pauda Silva L, Fernandez-Vina M, Chiattone A, Bosque D, Rondon G, Giralt S, Cooper L, Chen C, Parmar S, Jones R, Andersson B, Worth L, Alousi A, McNiece I, Komanduri K, Simmons P, Champlin R, Shpall E. Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). Blood 114(22):1318, 2009. e-Pub 2009.
275. Sola C, Silva L, Saliba R, de Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C. Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. Journal of Clinical Oncology 27(15s):365s, 2009. e-Pub 2009.
276. Andersson B, de Lima M, Worth L, Thall P, Popat U, Jones R, Shpall E, Hosing C, Madden T, Kazerooni R, McAdams P, Alousi A, Kebriaei P, Champlin R. Clofarabine + fludarabine with IV busulfan as reduced-toxicity conditioning therapy for allogeneic stem cell transplantation (Allo-SCT) in advanced myeloid leukemia/MDS. Bone Marrow Transplantation 43(Supplement 1):S44, 2009. e-Pub 2009.
277. Andersson B, de Lima M, Popat U, Jones R, Shpall E, Hosing C, McAdams P, Alousi A, Kebriaei P, Champlin R, Worth R, Madden T, Kazerooni R. Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia and MDS Using Clofarabine (CLO) + Fludarabine (Flu) with IV Busulfan (BU) as Conditioning Therapy. Biology of Blood and Marrow Transplantation 15(2 (Supplement 2)):86, 2009. e-Pub 2009.
278. Smith V, Hosing C, Popat U, Schnidler J. New Mobilization Strategies for Collecton of Peripheral Blood Progenitor Cells for Lymphoma and Myeloma Patients. Biology of Blood and Marrow Transplantation 15(2 (Supplement 2)):29, 2009. e-Pub 2009.
279. Silva D, Saliba R, Giralt S, Hosing C, Khouri I, Popat U, Qazilbash M, Shpall E, Thomas D, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients (Pts) with Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation 15(2 Supplement 2):63, 2009. e-Pub 2009.
280. Decker W, Li S, Xing D, Robinson S, Yang H, Steiner D, Lapushin R, Ramsey A, Hosing C, Gribben J, Keating M, Shpall E, Wierda W. Generation of CLL-Specific CTL Effectors from Partially HLA-Matched Umbilical Cord Blood Grafts Using CD154-Transduced CLL Cell S as APCS. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):123, 2009. e-Pub 2009.
281. Champlin R, de Lima M, Giralt S, Kebriaei P, Anderlini P, Qazilbash M, Hosing C, Shpall E, Fisher T, Gabriela R. Sequential Therapy with Nonablative Allogeneic Stem Cell Transplantation, Post-Transplant Imatinib and Donor Lymphocyte Infusion for Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation 15(2, Supplement 2):63, 2009. e-Pub 2009.
282. Walter K, Hosing C, Smith V, Rhodes B, Thompson R, Qazilbash M, McMannis J, Alousi A, de Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, Popat U. An Analysis of the Charges Associated with Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):71, 2009. e-Pub 2009.
283. Efebera Y, Saliba R, Thandi R, Popat U, de Lima M, a A, Hosing C, Ledford M, Champlin R, Giralt S. Impact of Pre-Stem Cell Transplant Ferritin Levels on Late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Transplant Outcomes. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):92, 2009. e-Pub 2009.
284. Anderson J, Gulbis A, Cool R, Westmoreland M, de Lima M, Giralt S, Hosing C, Popat U, Qazilbash M, Shpall E, Khouri I, Champlin R, Kebriaei P. Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation 15(2 Supplement 2):113, 2009. e-Pub 2009.
285. Xing D, Ramsay A, Gribben J, Decker W, Li S, Robinson S, Yang H, David S, Hosing C, Elizabeth S, Zweidler-McKay P, Bollard C. Defective Immune Synapse Formation of Umbilical Cord Blood-Derived Natural Killer Cell S is Abrogated by Ex Vivo Expansion. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):117, 2009. e-Pub 2009.
286. Kebriaei P, Munsell M, Gutierrez K, de Lima M, Giralt S, Hosing C, Popat U, Qazilbash M, Thomas D, Kantarjian H, Khouri I, Champlin R. Inferior Outcome with Addition of Rituximab for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation 15(2 Supplement 2):117, 2009. e-Pub 2009.
287. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Padua L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BUFLU) Conditioning Regimen. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):106, 2009. e-Pub 2009.
288. Ciurea S, de Lima M, Giralt S, Alousi A, Kebriaei P, Khouri I, Anderlini P, Andersson B, Hosing C, Champlin R, Popat U. Outcomes of Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):62, 2009. e-Pub 2009.
289. de Lima M, McNiece I, McMannis J, Hosing C, Kebriaei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double Cord Blood Transplantation (CBT) with Ex-Vivo Expansion (EXP) of One Unit Utilizing a Mesenchymal Stromal Cell (MSC) Platform. Biology of Blood and Marrow Transplantation 15(2 (Supplement 2)):47, 2009. e-Pub 2009.
290. Pelosini M, Mendoza F, Hosing C, Popat U, Anderlini P, Alousi A, Kebriaei P, Weber D, Wang M, Champlin R, Giralt S, Qazilbash M. Improved Outcome for Allogeneic Transplantation Performed After January 2000. Biology of Blood and Marrow Transplantation 15(2 Supplement 2):168, 2009. e-Pub 2009.
291. Hosing C, Smith V, Rhodes B, Walter K, Thompson R, Qazilbash M, McMannis J, Champlin R, Popat U, Giralt S. An Analysis of the Charges Associated with Peripheral Blood Hematopoietic Progenitor Cell (HPC). Clinical Lymphoma and Myeloma 9(Supplement 1):S51, 2009. e-Pub 2009.
292. Ciurea S, Kebriaei P, Khouri I, Qazilbash M, Jones R, Petropoulos D, Worth L, Alousi A, Hosing C, Cano P, McMannis J, Giralt S, Fernandez-Vina M, Shpall E, de Lima M. Fludarabine, Melphalan and Thiotepa Conditioning For Unrelated Donor Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 15(2 (Supplement 2)):48, 2009. e-Pub 2009.
293. Giralt S, Saliba R, Rondon G, de Pauda Silva L, Alousi A, Popat U, de Lima M, Andersson B, Kebriaei P, Anderlini P, Hosing C, Jones R, Shpall E, Champlin R, Khouri I. Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent. Proc of Amer Soc of Hematology 112(11):750, 2008. e-Pub 2008.
294. Xiao N, Shiue L, Arias-Mendoza P, Aakhus E, Hosing C, Duvic M. Foxp3 Expression Is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Proc of Amer Soc of Hematology 112(11):1001, 2008. e-Pub 2008.
295. Popat U, Saliba R, de Padua Silva L, Andersson B, Alousi A, Anderlini P, de Lima M, Okoroji G, Hosing C, Jones R, Qazilbash M, Champlin R, Giralt. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Proc of Amer Soc of Hematology 112(11):297, 2008. e-Pub 2008.
296. Popat U, de Lima M, Ativitavas T, Rondon G, de Padua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash M, Andersson B, Champlin R. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome: Recent MDACC Experience. Proc of Amer Soc of Hematology 112(11):413, 2008. e-Pub 2008.
297. Popat U, de Lima M, Ativitavas T, Rondon G, de Pdua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash M, Andersson B, Champlin R. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome: Recent MDACC Experience. Proc of Amer Soc of Hematology 112(11):413, 2008. e-Pub 2008.
298. de Lima M, de Padua Silva L, Giralt S, Komanduri K, Andersson B, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Proc of Amer Soc of Hematology 112(11):414, 2008. e-Pub 2008.
299. Khouri I, Lopez A, Okoroji G, Korbling M, McCormick G, Hsu Y, de Padua Silva L, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt S, de Lima M, Anderlini P, Popat U, Qazilbash M, Champlin R, Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantation (Auto) in First Remission. Proc of Amer Soc of Hematology 112(11):417, 2008. e-Pub 2008.
300. de Lima M, McMannis J, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, de Padua Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson B, Nieto Y, Ciurea S, Komanduri K, Champlin R, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Proc of the Amer Soc of Hematology 112(11):63, 2008. e-Pub 2008.
301. Khouri I, Bassett R, Samuels B, Maadani F, Okoroji G, Harrell R, Giralt S, de Lima M, Anderlini P, Popat U, Valverde R, Hsu Y, Hagemeister F, Laughlin P, Medeiros J. Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO). Proc of Amer Soc of Hematology 112(11):416, 2008. e-Pub 2008.
302. Khan Z, Saliba R, Qureshi S, Hosing C, Giralt S, de Lima M, Yusuf S, Popat U, Champlin R, Qazilbash M. Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Proc of Amer Soc of Hematology 112(11):1135, 2008. e-Pub 2008.
303. Hosing C, Smith V, Rhodes B, Walters K, Qazilbash M, McMannis J, Alousi A, de Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, Popat U. An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Proc of Amer Soc of Hematology 112(11):828, 2008. e-Pub 2008.
304. Ciurea S, de Lima M, Giralt S, Qazilbash M, Alousi A, Kebriaei P, Khouri I, Anderlini P, Andersson B, Hosing C, Verovsek S, Kantarjian H, Champlin R, Popat U. Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Proc of Amer Soc of Hematology 112(11):1131, 2008. e-Pub 2008.
305. Khouri I, Bassett R, Hsu Y, Dickerson T, Acholonu S, Harrell R, Okoroji G, de Padua Silva L, Korbling M, Alousi A, Hosing C, Popat U, Giralt S, Kebriaei P, Qazilbash M, Ledesma C, Keating M, Champlin R, Bueso-Ramos C. Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. Proc of the Amer Soc of Hematology 112(11):413, 2008. e-Pub 2008.
306. de Padua Silva L, Cortes J, Jabbour E, Giralt S, Kebriaei P, O'Brien S, Alousi A, Qazilbash M, Rondon G, Ravandi F, Ribeiro R, Hosing C, Kantarjian H, Champlin R, de Lima M. Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. Proc of Amer Soc of Hematology 112(11):750, 2008. e-Pub 2008.
307. Qazilbash M, Saliba R, Pelosini M, Hosing C, Mendoza F, Han E, Wang M, Weber D, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Orlowski R, Champlin R, Giralt S. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Proc of Amer Soc of Hematology 112(11):1140, 2008. e-Pub 2008.
308. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Pauda Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for patients in the 6th and 7th Decades of Life with AML or MDS. Proc of Amer Soc of Hematology 112(11):1031, 2008. e-Pub 2008.
309. Tam C, Bassett R, Ledesma C, Korbling M, Okoroji G, Harrell R, Hsu Y, de Padua Silva L, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt S, de Lima M, Anderlini P, Popat U, Qazilbash M, Samuels B, Champlin R, Khouri I. Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission but Not for Patients with Recurrent Disease. Proc of Amer Soc of Hematology 112(11):417, 2008. e-Pub 2008.
310. Ramos C, Saliba R, Khorshid O, de Padua L, Giralt S, Andersson B, Ueno N, Shpall E, Hosing C, Qureshi S, Champlin R, de Lima M. Serological Evidence of Hepatitis C is Associated with Worse Non-Relapse Mortality and overall Survival After Allogeneic Stem Cell Transplantation. Proc of the Amer Soc of Hematology 14(2:2):103, 2008. e-Pub 2008.
311. Popat U, Saliba R, Ablawat S, Okoroji G, Alousi A, Anderlini P, Andersson B, de Lima M, Jones R, Kebriaei P, Korbling M, Nieto Y, Qazilbash M, Shpall E, Khouri I, Giralt S, Champlin R, Hosing C. Incidence and Factors influencing stem cell mobilization in patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). Proc of the Amer Soc of Hematology 14(2:2):37, 2008. e-Pub 2008.
312. Petropoulos D, Giralt S, Andersson B, Chan K, Rondon G, Popat U, Hosing C, Alousi A, Champlin R, de Lima M. Central Nervous System (CNS) Involvement at Diagnosis Does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for patients with Acute Myeloid Leukemia (AML). Proc of the Amer Soc of Hematology 14(2:2):61, 2008. e-Pub 2008.
313. Anderlini P, Saliba R, Acholonu S, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Champlin R. Two-Year Follow-Up Results at the M. D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantaton with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin’s Lymphoma. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
314. Qazilbash M, Findani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi P, Weber D, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
315. Qazilbash M, Gul Z, Findani S, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, de Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
316. Gulbis A, Hsu Y, Neumann J, Hymes S, de Lima M, Hosing C, Khouri I, Qazilbash M, Kebriaei P, Andersson B, Champlin R, Couriel D. Etanercept as Salvage Therapy for Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
317. Qazilbash M, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, De Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Blood, 2006. e-Pub 2006.
318. Ahmed B, Saliba R, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber D, Wang M, Couriel D, Popat U, Kebriaei P, Alousi, Champlin R, Giralt S, Qazilbash. Deletion of the Short Arm of Chromosome 1 (del 1P) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Blood, 2006. e-Pub 2006.
319. Qazilbash M, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, De Lima M, Champlin R, Giralt S. Salvage Autologous Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 12(2)Supplement 1 (348) 12, 2006. e-Pub 2006.
320. Hosing C, Saliba R, Okoroji G, Popat U, Couriel D, Kebriaei P, Ali T, de Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin R, Khouri I. High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age. Blood, 2006. e-Pub 2006.
321. Kebriaei P, Madden T, Thapar N, Shpall E, Hosing C, Qazilbash M, de Lima M, Thall P, Wright S, Khouri I, Champlin R, Jones R, Andersson B. Intravenous (i.v) Busulfan (Bu) Plus Melphalan (Mel) is a Well-Tolerated Preparative Regimen for Stem Cell Transplantation (SCT) in Patients (pts) with Advanced Lymphoid Malignancies. Biology of Blood and Marrow Transplantation 12, 2006. e-Pub 2006.
322. Hosing C, Donato M, Khouri I, Cu D, Bethancourt D, Acholonu S, Giralt S, Duvic M, Champlin R. Allogeneic hematopoietic stem cell transplantation for cutaneous T-cell lymphoma (CTCL). Journal of Clinical Oncology 24, 2006. e-Pub 2006.
323. Anderlini P, Saliba R, Acholonu S, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Couriel D, Champlin R. Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin’s Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors. Blood, 2006. e-Pub 2006.
324. Qazilbash M, Saliba R, Davis M, Mendoza F, Hosing C, Couriel D, de Lima M, Kebriaei P, Weber D, Wang M, Alousi A, Matthes S, Jones R, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood, 2006. e-Pub 2006.
325. Kebriaei P, Detry M, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri I, Anderlini P, Hosing C, Alousi A, Giralt S, Champlin R, de Lima M. Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML). Blood, 2006. e-Pub 2006.
326. Khouri I, Saliba R, Hosing C, Valverde R, Erwin W, Favad L, Maadani F, Korbling M, Okoroji G, Stachowiak A, Samuels B, Anderlini P, Couriel D, de Lima M, Giralt S, Popat U, Kebriaei P, Ueno N, Qazilbash M, McLaughlin P, Hagemeister F, Younes A, Podoloff D, Champlin R. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). Blood, 2006. e-Pub 2006.
327. deSouza J, Saliba R, Patah P, Rondon G, Qazilbash M, Hosing C, Popat U, Champlin R. Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2006. e-Pub 2006.
328. Qazilbash M, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, de Lima M, Champlin R, Giralt S. Salvage Non-Myeloablative Allogeneic Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 12(2), 2006. e-Pub 2006.
329. Kebriaei P, Madden T, Thapar N, Shpall E, Hosing C, Qazilbash M, Thall P, Khouri I, Champlin R, Jones R, Andersson. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for stem cell transplantation (SCT) in patients (pts) with advanced lymphoid malignancies. Journal of Clinical Oncology 24, 2006. e-Pub 2006.
330. de Lima M, Patah P, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriaei P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri K, Champlin R, Shpall E. Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT). Blood, 2006. e-Pub 2006.
331. de Lima M, Parmar S, Liu P, Patah P, Cano P, Shpall E, Hosing C, Couriel D, Anderlini P, Giralt S, Andersson B, Kebriaei P, Rondon G, Champlin R, Fernandez-Vina M. HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT). Blood, 2006. e-Pub 2006.
332. Alousi A, Saliba R, Okoroji G, Hosing C, Samuels B, Champlin R, Khouri I. The influence of PET/Gallium (P/G) status and high-dose rituximab (HDR) in patients (pts) with aggressive, large, B-cell lymphoma (LBCL) receiving autologous stem cell transplants (ASCT). Journal of Clinical Oncology 24, 2006. e-Pub 2006.
333. Alousi A, Saliba R, Okoroji G, Hosing C, Samuels B, Champlin R, Khouri I. The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT). Blood, 2006. e-Pub 2006.
334. Saliba R, Khouri I, de Lima M, Hosing C, Okoroji G, Acholonu S, Maadani F, De Jesus J, Hsu Y, Champlin R, Couriel D. Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin’s Lymphoma. Blood, 2006. e-Pub 2006.
335. Champlin R, Hagemeister F, Hosing C, Kwak L, O’Brien S, Rodriguez M, Verstovsek S, Pro B. Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome. Blood, 2006. e-Pub 2006.
336. Shpall E, Karandish S, Sadeghi T, Hosing C, Garcia C, Cherry M, Walker J, Denman C, Saliba R, Champlin R, Fernandez-Vina M, Cano P, McMannis J. In Utero is Superior to Ex Utero Cord Blood Collection. Blood, 2006. e-Pub 2006.
337. Kebriaei P, Giralt S, Madden T, Thapar N, Shpall E, Hosing C, Qazilbash M, Couriel D, Popat U, Thall P, Champlin R, Jones R, Andersson B. Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM). Blood, 2006. e-Pub 2006.

Book Chapters

1. Bashir Q, Hosing C, Popat U. Allogeneic Transplantation. In: Allogeneic Transplantation. 5th. McGraw Hill Publishing, 2024.
2. Alsfeld, LC, Hosing, C. Hematopoietic Cell Collection. In: Manual of Hematopoietic Cell Collection and Cellular Therapies. Elsiever, 29-37, 2024.
3. Alsfeld L, Hosing C. Hematopoietic cell collection. In: in Manual of Stem Cell Transplantation and Cellular Therapies for Hematologic Malignancies. Elseiver, 2022.
4. Mehta RS, Hosing C. Allogeneic Transplantation. In: MD Anderson Manual of Medical Oncology, 4th ed. McGraw Hill, 2022.
5. Wilson JM, Eaton EN, Pool K, Reioux D, Fontenot M, Marin D, Champlin R, Rezvani K, Shpall EJ, Hosing C. Design and Licensure of an American Cord Blood Bank. In: Cell Therapy: cGMP Facilities and Manufacturing. Springer, 2022.
6. Gowda L, Hosing C. Hyperleukocyosis. In: Oncologic Critical Care. Springer Press, 2019.
7. Arslan S, Hosing C. Hematopoietic Stem Cell Transplantation for Rare Hematologic Malignancies. In: Hematopoietic Cell Transplantation for Malignant Conditions. Elsevier, 2018.
8. Hosing C, Champlin RE. Stem Cell Transplantation for Treatment of Non Hodgkin's Lymphoma. In: Lymphoma, Diagnosis and Treatment. Humana Press, 371-402, 2013.
9. Hosing C, Anderlini P. Autologous and Allogeneic Peripheral Blood Stem Cell Collection. In: BMT supportive care manual. Summit Communications, 2007.
10. Hosing C, Anderlini P. Management of Related and Unrelated Donors. In: Clinical Bone Marrow and Stem Cell Transplantation. Third. Cambridge University Press, 404-415, 2004.
11. Gowda, L, Hosing C. Malignant Hematological Diseases: Hyperleukocytosis. In: Oncologic Critical Care Textbook. Springer Nature Meteor.